NOX4 inhibitors and methods of making and using same

Abstract

The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis) and acute respiratory distress syndrome (ARDS) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Description

NOX4 INHIBITORS AND METHODS OF MAKING AND USING SAME CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This Application claims the benefit of U.S. Application No.63 / 535,226, filed on August 29, 2023, the contents of which are incorporated herein by reference in their entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under grant number W81XWH-17-1- 0443 awarded by the Department of Defense. The government has certain rights in the invention. BACKGROUND

[0003] The regulation of redox homeostasis is crucial for the maintenance of normal cellular growth, metabolism, and survival. Oxidative stress is defined as the imbalance between the production of reactive oxygen species (ROS) and the capability of the cell to elicit an effective antioxidant response. Several sources of ROS in cells and tissue have been identified, including mitochondrial electron transfer chain (Liu et al. (2002) J. Neurochem.80(5): 780-787) and NADPH oxidase (NOX) enzymes (Bedhard and Krause (2007) Physiol. Rev.87(1): 245-313). NOX-derived ROS have been identified as the main source of oxidative stress, which promotes key events in the development of fibrotic diseases (such as skin fibrosis (Babalola et al. (2014) Arch. Dermatol. Res.306(4): 313-330), idiopathic pulmonary fibrosis (IPF) (Hecker et al. (2012) Cell Mol. Life Sci.69(14): 2365-2371), liver fibrosis (Minicis and Brenner (2007) Arch. Biochem. Biophys.462(2): 266-272), and kidney fibrosis (Holterman et al. (2015) Clin. Sci. (Lond.) 128(8): 465-481), and acute respiratory distress syndrome (ARDS) (Kellner et al. (2017) Pulmonary Vasculature Redox Signaling in Health and Disease 967: 105-137).

[0004] Fibrosis is a complex disease characterized by excessive synthesis and accumulation of extracellular matrices that occur as a result of activation and proliferation of fibroblasts and myofibroblasts. Notably, nearly 45% of all naturally-occurring deaths in the western world are attributed to some form of fibrotic disease (Bitterman and Henke (1991) Chest 99(3 Suppl): 81s- 84s). Briefly, the presence of ROS is believed to activate transforming growth factor beta (TGF-  β) signaling pathways, then induces elevated production of NOX4-generated ROS (Chen et al. (2013) Biochem. Biophys. Res. Commun.430(3): 918-925). The presence of NOX4-generated ROS, in turn, activates various pathways that ultimately lead to fibrosis. Indeed, NOX4 mRNA expression has been found to be upregulated in both pulmonary fibroblasts isolated from IPF patients (Amara et al. (2010) Thorax 65(8): 733-738) and skin fibroblasts from scleroderma patients (Spadoni et al. (2015) Arthritis Rheumatol.67(6): 1611-1622), as well as in a number of in vivo fibrosis models, including liver fibrosis (Aoyama et al. (2012) Hepatology (Baltimore Md.) 56(6): 2316-2327), pulmonary fibrosis (Jarman et al. (2014) Am. J. Respir. Cell Mol. Biol. 50(1): 158-169; Hecker et al. (2009) Nat. Med.15 (9): 1077-1081), and diabetic neuropathy (kidney fibrosis associated with diabetes mellitus) (Sedeek et al. (2010) Am. J. Physiol. – Renal Physiol.299(6): F1348-F1358). In view of such research, suppression of NOX4 activity (by, for example, a NOX4 inhibitor) has been investigated as a possible route for treating fibrotic disorders. See, e.g., U.S. Patent No.10,654,802.

[0005] ARDS is a critical syndrome caused by heterogeneous pathologic factors and characterized by acute development of respiratory failure, bilateral diffuse lung infiltrations, and severe hypoxemia. See, e.g., Kellner et al. (2017) Pulmonary Vasculature Redox Signaling in Health and Disease 967: 105-137. The severity of ARDS is associated with poor prognosis and higher mortality. Id. Moreover, the recent global COVID-19 pandemic has attenuated the urgent need to address ARDS, as this syndrome is the leading cause of death among COVI-19 patients (Wu C, et al. (2020) JAMA Intern Med). Critical pathological features of ARDS (e.g., loss of lung endothelial barrier integrity and inflammatory injury) are strongly associated with increased oxidative stress; however, clinical trials using antioxidant treatments have failed to reduce mortality in ARDS patients.

[0006] Importantly, no cure for most of these diseases has yet been identified. Current approaches to treating fibrotic diseases, for example, have thus far remained limited to attempts at slowing down disease progression (e.g., via administration of pirfenidone for pulmonary fibrosis). Thus, new treatments are desired. Accordingly, there exists a need forNOX4 inhibitors for use in the treatment of fibrotic disorders and ARDS. SUMMARY

[0007] In accordance with the purpose(s) of the invention, as embodied and broadly describedherein, the invention, in one aspect, relates to compounds, compositions, and methods for inhibiting Nox4 signaling. The disclosed compounds and compositions can be useful in, for example, the treatment of fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis) and acute respiratory distress syndrome (ARDS).

[0008] Thus, disclosed are compounds having a structure represented by a formula:wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: A is ‒C(O)‒; or L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when either: n is 1; or is a double bond, Q1is ‒N=, and Q2is ‒CH=, and R3is ‒NR12aR12b, then R12ais hydrogen or C1-C4 alkyl.

[0009] Also disclosed are pharmaceutical compositions comprising an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl,or wherein each of R10cand R10dtogether comprise =O, or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:wherein * denotes a bond connected to:and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substitutedwith 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0010] Also disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell, the method comprising contacting the cell with an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl,C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0011] Also disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selectedfrom hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0012] Also disclosed are methods of treating a fibrotic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independentlyselected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0013] Also disclosed are kits comprising a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen and C1-C4 alkyl; and wherein R12bis selected from C1- C4 alkyl and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl, and one or more selected from: (a) an anti-fibrotic agent; and (b) instructions for treating a fibrotic disorder.

[0014] Also disclosed are methods of treating acute respiratory distress syndrome (ARDS) in asubject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

[0015] Also disclosed are kits comprising a compound having a structure represented by aformula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each ofR11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, and one or more selected from: (a) an agent known to treat ARDS; and (b) instructions for treating ARDS.

[0016] Also disclosed are compounds selected from:, or a pharmaceutically acceptable salt thereof.

[0017] Also disclosed are pharmaceutical compositions comprising an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0018] Also disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell, the method comprising contacting the cell with an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof.

[0019] Also disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof.

[0020] Also disclosed are methods of treating a fibrotic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound, ora pharmaceutically acceptable salt thereof.

[0021] Also disclosed are methods of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof.

[0022] Also disclosed are kits comprising a disclosed compound or a pharmaceutically acceptable salt thereof, and one or more selected from: (a) an anti-fibrotic agent; (b) instructions for treating a fibrotic disorder; (c) an agent known to treat ARDS; and (d) instructions for treating ARDS.

[0023] Also disclosed are compounds selected from:, ,  ,     ,   ,  or a pharmaceutically acceptable salt thereof.

[0024] Also disclosed are pharmaceutical compositions comprising an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0025] Also disclosed are methods of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.

[0026] Also disclosed are kits comprising a disclosed compound, and one or more selected from: (a) an agent known to treat ARDS; and (b) instructions for treating ARDS.

[0027] Also disclosed are methods of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:wherein q is 1 or 2; wherein each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1- C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein each of R6aand R6bis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R6aand R6btogether comprise =O;and wherein R7is selected from hydrogen and C1-C4 alkyl; and wherein R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2(C1-C4 alkyl), ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒ SO2Cy2; wherein each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3; and wherein Cy3, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl; and wherein Cy2, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3; wherein r is 0, 1, or 2; and wherein Ar3, when present, is selected from C6 aryl and C2-C5 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4; wherein each of R14aand R14b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy5; and wherein Cy5, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Cy4, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or apharmaceutically acceptable salt thereof.

[0028] Also disclosed are kits comprising a compound having a structure represented by a formula:, wherein q is 1 or 2; wherein each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1- C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein each of R6aand R6bis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R6aand R6btogether comprise =O; and wherein R7is selected from hydrogen and C1-C4 alkyl; and wherein R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒SO2Cy2; wherein each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3; and wherein Cy3, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl; and wherein Cy2, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr3, and ‒ NH(CH2)rAr3; wherein r is 0, 1, or 2; and wherein Ar3, when present, is selected from C6 aryl and C2-C5 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4; wherein each of R14aand R14b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy5; and wherein Cy5, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Cy4, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, and one or more selected from: (a) an agent known to treat ARDS; and (b) instructions for treating ARDS.

[0029] While aspects of the present invention can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of the present invention can be described and claimed in any statutory class. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification. BRIEF DESCRIPTION OF THE FIGURES

[0030] The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain theprinciples of the invention.

[0031] FIG.1A and FIG.1B show a representative diagram illustrating a 2-hit preclinical aging muring model of severe ARDS and representative data comparing lung injury scores for young and aged mice, respectively.

[0032] FIG.2A and FIG.2B show representative data illustrating that senescent ECs exhibit impaired barrier-regulatory responses.

[0033] FIG.3A and FIG.3B show representative data illustrating that redox imbalance in senescent ECs corresponds with elevated Nox4 levels.

[0034] FIG.4 shows representative data illustrating that age-dependent severe pre-clinical ARDS is associated with sustained Nox4 levels and excessive ROS production.

[0035] FIG.5A-F show representative data illustrating that aged Nox4-eKO mice demonstrate striking protection from ALI.

[0036] FIG.6A-D shows representative data pertaining to the identification of novel Nox4 inhibitors.

[0037] FIG.7A and FIG.7B show representative data illustrating that Nox4 inhibitors reverse established pro-fibrotic phenotypes in human IPF lung myofibroblasts.

[0038] FIG.8A-G show representative data illustrating that Nox4 inhibitor UANOX48 protects from pre-clinical ARDS.

[0039] FIG.9 shows representative structures of Nox4 inhibitors for IV delivery.

[0040] FIG.10A and FIG.10B show representative diagrams of the efficacy testing protocols.

[0041] FIG.11A and FIG.11B show representative planned variants of APV235197A.

[0042] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or can be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. DETAILED DESCRIPTION

[0043] The present invention can be understood more readily by reference to the following detailed description of the invention and the Examples included therein.

[0044] Before the present compounds, compositions, articles, systems, devices, and / or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.

[0045] While aspects of this disclosure can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of this disclosure can be described and claimed in any statutory class. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or description that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.

[0046] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon. Nothing herein is to be construed as an admission that the present application is not entitled to antedate such publication by virtue of prior invention. Further, stated publication dates may be different from actual publication dates, which can require independent confirmation. A. DEFINITIONS

[0047] As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example,reference to “a functional group,” “an alkyl,” or “a residue” includes mixtures of two or more such functional groups, alkyls, or residues, and the like.

[0048] As used in the specification and in the claims, the term “comprising” can include the aspects “consisting of” and “consisting essentially of.”

[0049] Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0050] As used herein, the terms “about” and “at or about” mean that the amount or value in question can be the value designated some other value approximately or about the same. It is generally understood, as used herein, that it is the nominal value indicated ±10% variation unless otherwise indicated or inferred. The term is intended to convey that similar values promote equivalent results or effects recited in the claims. That is, it is understood that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but can be approximate and / or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art. In general, an amount, size, formulation, parameter or other quantity or characteristic is “about” or “approximate” whether or not expressly stated to be such. It is understood that where “about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.

[0051] References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.

[0052] A weight percent (wt. %) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.

[0053] As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0054] As used herein, the term “subject” can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, the subject of the herein disclosed methods can be a human, non- human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. In one aspect, the subject is a mammal. A patient refers to a subject afflicted with a disease or disorder. The term “patient” includes human and veterinary subjects.

[0055] As used herein, the term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various aspects, the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease. In one aspect, the subject is a mammal such as a primate, and, in a further aspect, the subject is a human. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock(e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.).

[0056] As used herein, the term “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.

[0057] As used herein, the term “diagnosed” means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the compounds, compositions, or methods disclosed herein.

[0058] As used herein, the terms “administering” and “administration” refer to any method of providing a pharmaceutical preparation to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.

[0059] As used herein, the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors wellknown in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.

[0060] As used herein, “dosage form” means a pharmacologically active material in a medium, carrier, vehicle, or device suitable for administration to a subject. A dosage form can comprise a disclosed compound, a product of a disclosed method of making, or a salt, solvate, or polymorph thereof, in combination with a pharmaceutically acceptable excipient, such as a preservative, buffer, saline, or phosphate buffered saline. Dosage forms can be made using conventional pharmaceutical manufacturing and compounding techniques. Dosage forms can comprise inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants (e.g., ascorbic acid, alpha- tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene9-10 nonyl phenol, sodium desoxycholate), solution and / or cryo / lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic adjustment agents (e.g., salts or sugars), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsilozone), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymeric stabilizers and viscosity-adjustment agents (e.g., polyvinylpyrrolidone, poloxamer 488, carboxymethylcellulose) and co-solvents (e.g., glycerol, polyethylene glycol, ethanol). A dosage form formulated for injectable use can have a disclosed compound, a product of a disclosed method of making, or a salt, solvate, or polymorph thereof, suspended in sterile saline solution for injection together with a preservative.

[0061] As used herein, “kit” means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual membercomponents may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.

[0062] As used herein, “instruction(s)” means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents, and are meant to include future updates.

[0063] As used herein, the terms “therapeutic agent” include any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to an organism (human or nonhuman animal), induces a desired pharmacologic, immunogenic, and / or physiologic effect by local and / or systemic action. The term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs and the like. Examples of therapeutic agents are described in well-known literature references such as the Merck Index (14thedition), the Physicians' Desk Reference (64thedition), and The Pharmacological Basis of Therapeutics (12thedition) , and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. For example, the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti-inflammatory agents, anti-epileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants,anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiadrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics; antispasmodics, cardiovascular preparations (including calcium channel blockers, beta-blockers, beta-agonists and antiarrythmics), antihypertensives, diuretics, vasodilators; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones; bone growth stimulants and bone resorption inhibitors; immunosuppressives; muscle relaxants; psychostimulants; sedatives; tranquilizers; proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced); and nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including both double- and single-stranded molecules, gene constructs, expression vectors, antisense molecules and the like), small molecules (e.g., doxorubicin) and other biologically active macromolecules such as, for example, proteins and enzymes. The agent may be a biologically active agent used in medical, including veterinary, applications and in agriculture, such as with plants, as well as other areas. The term "therapeutic agent" also includes without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; or substances which affect the structure or function of the body; or pro- drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.

[0064] The term “pharmaceutically acceptable” describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.

[0065] As used herein, the term “derivative” refers to a compound having a structure derived from the structure of a parent compound (e.g., a compound disclosed herein) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds. Exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound.

[0066] As used herein, the term “pharmaceutically acceptable carrier” refers to sterile aqueous ornonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.

[0067] A residue of a chemical species, as used in the specification and concluding claims, refers to the moiety that is the resulting product of the chemical species in a particular reaction scheme or subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species. Thus, an ethylene glycol residue in a polyester refers to one or more -OCH2CH2O- units in the polyester, regardless of whether ethylene glycol was used to prepare the polyester. Similarly, a sebacic acid residue in a polyester refers to one or more -CO(CH2)8CO- moieties in the polyester, regardless of whether the residue is obtained by reacting sebacic acid or an ester thereof to obtain the polyester.

[0068] As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described below. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms, such as nitrogen, can have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds. Also, the terms “substitution” or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. It is also contemplated that, in certain aspects, unless expressly indicated to the contrary, individual substituents can be further optionally substituted (i.e., further substituted or unsubstituted).

[0069] In defining various terms, “A1,” “A2,” “A3,” and “A4” are used herein as generic symbols to represent various specific substituents. These symbols can be any substituent, not limited to those disclosed herein, and when they are defined to be certain substituents in one instance, they can, in another instance, be defined as some other substituents.

[0070] The term “aliphatic” or “aliphatic group,” as used herein, denotes a hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic (including fused, bridging, and spirofused polycyclic) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1- 20 carbon atoms. Aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0071] The term “alkyl” as used herein is a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t- butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl,tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group can be cyclic or acyclic. The alkyl group can be branched or unbranched. The alkyl group can also be substituted or unsubstituted. For example, the alkyl group can be substituted with one or more groups including, but not limited to, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo- oxo, or thiol, as described herein. A “lower alkyl” group is an alkyl group containing from one to six (e.g., from one to four) carbon atoms. The term alkyl group can also be a C1 alkyl, C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C1-C6 alkyl, C1-C7 alkyl, C1-C8 alkyl, C1-C9 alkyl, C1-C10 alkyl, and the like up to and including a C1-C24 alkyl.

[0072] Throughout the specification “alkyl” is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group. For example, the term “halogenated alkyl” or “haloalkyl” specifically refers to an alkyl group that is substituted with one or more halide, e.g., fluorine, chlorine, bromine, or iodine. Alternatively, the term “monohaloalkyl” specifically refers to an alkyl group that is substituted with a single halide, e.g. fluorine, chlorine, bromine, or iodine. The term “polyhaloalkyl” specifically refers to an alkyl group that is independently substituted with two or more halides, i.e. each halide substituent need not be the same halide as another halide substituent, nor do the multiple instances of a halide substituent need to be on the same carbon. The term “alkoxyalkyl” specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below. The term “aminoalkyl” specifically refers to an alkyl group that is substituted with one or more amino groups. The term “hydroxyalkyl” specifically refers to an alkyl group that is substituted with one or more hydroxy groups. When “alkyl” is used in one instance and a specific term such as “hydroxyalkyl” is used in another, it is not meant to imply that the term “alkyl” does not also refer to specific terms such as “hydroxyalkyl” and the like.

[0073] This practice is also used for other groups described herein. That is, while a term such as “cycloalkyl” refers to both unsubstituted and substituted cycloalkyl moieties, the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substituted alkoxy can be specifically referred to as, e.g., a “halogenated alkoxy,” a particular substituted alkenyl can be, e.g., an “alkenylalcohol,” and the like. Again, the practice of using a general term, such as “cycloalkyl,” and a specific term, such as “alkylcycloalkyl,” is not meant to imply that thegeneral term does not also include the specific term.

[0074] The term “cycloalkyl” as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, and the like. The term “heterocycloalkyl” is a type of cycloalkyl group as defined above, and is included within the meaning of the term “cycloalkyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted. For example, the cycloalkyl group and heterocycloalkyl group can be substituted with 0, 1, 2, 3, or 4 groups independently selected from C1-C4 alkyl, C3-C7 cycloalkyl, C1-C4 alkoxy, −NH2, (C1-C4) alkylamino, (C1-C4)(C1-C4) dialkylamino, ether, halogen, −OH, C1-C4 hydroxyalkyl, −NO2, silyl, sulfo-oxo, −SH, and C1-C4 thioalkyl, as described herein.

[0075] The term “polyalkylene group” as used herein is a group having two or more CH2groups linked to one another. The polyalkylene group can be represented by the formula —(CH2)a—, where “a” is an integer of from 2 to 500.

[0076] The terms “alkoxy” and “alkoxyl” as used herein to refer to an alkyl or cycloalkyl group bonded through an ether linkage; that is, an “alkoxy” group can be defined as —OA1where A1is alkyl or cycloalkyl as defined above. “Alkoxy” also includes polymers of alkoxy groups as just described; that is, an alkoxy can be a polyether such as —OA1—OA2or —OA1—(OA2)a—OA3, where “a” is an integer of from 1 to 200 and A1, A2, and A3are alkyl and / or cycloalkyl groups.

[0077] The term “alkenyl” as used herein is a hydrocarbon group of from 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon double bond. Asymmetric structures such as (A1A2)C=C(A3A4) are intended to include both the E and Z isomers. This can be presumed in structural formulae herein wherein an asymmetric alkene is present, or it can be explicitly indicated by the bond symbol C=C. The alkenyl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.

[0078] The term “cycloalkenyl” as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms and containing at least one carbon-carbon double bound, i.e., C=C. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl,cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbornenyl, and the like. The term “heterocycloalkenyl” is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkenyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkenyl group and heterocycloalkenyl group can be substituted or unsubstituted. For example, the cycloalkenyl group and heterocycloalkenyl group can be substituted with 0, 1, 2, 3, or 4 groups independently selected from C1-C4 alkyl, C3-C7 cycloalkyl, C1-C4 alkoxy, C2-C4 alkenyl, C3-C6 cycloalkenyl, C2-C4 alkynyl, aryl, heteroaryl, aldeyhyde, −NH2, (C1-C4) alkylamino, (C1-C4)(C1-C4) dialkylamino, carboxylic acid, ester, ether, halogen, −OH, C1-C4 hydroxyalkyl, ketone, azide, −NO2, silyl, sulfo-oxo, −SH, and C1-C4 thioalkyl, as described herein.

[0079] The term “alkynyl” as used herein is a hydrocarbon group of 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon triple bond. The alkynyl group can be unsubstituted or substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.

[0080] The term “cycloalkynyl” as used herein is a non-aromatic carbon-based ring composed of at least seven carbon atoms and containing at least one carbon-carbon triple bound. Examples of cycloalkynyl groups include, but are not limited to, cycloheptynyl, cyclooctynyl, cyclononynyl, and the like. The term “heterocycloalkynyl” is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkynyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkynyl group and heterocycloalkynyl group can be substituted or unsubstituted. The cycloalkynyl group and heterocycloalkynyl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described herein.

[0081] The term “aromatic group” as used herein refers to a ring structure having cyclic clouds of delocalized π electrons above and below the plane of the molecule, where the π clouds contain (4n+2) π electrons. A further discussion of aromaticity is found in Morrison and Boyd, OrganicChemistry, (5th Ed., 1987), Chapter 13, entitled “Aromaticity,” pages 477-497, incorporated herein by reference. The term “aromatic group” is inclusive of both aryl and heteroaryl groups.

[0082] The term “aryl” as used herein is a group that contains any carbon-based aromatic group including, but not limited to, benzene, naphthalene, phenyl, biphenyl, anthracene, and the like. The aryl group can be substituted or unsubstituted. The aryl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, ─NH2, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described herein. The term “biaryl” is a specific type of aryl group and is included in the definition of “aryl.” In addition, the aryl group can be a single ring structure or comprise multiple ring structures that are either fused ring structures or attached via one or more bridging groups such as a carbon-carbon bond. For example, biaryl can be two aryl groups that are bound together via a fused ring structure, as in naphthalene, or are attached via one or more carbon-carbon bonds, as in biphenyl.

[0083] The term “aldehyde” as used herein is represented by the formula —C(O)H. Throughout this specification “C(O)” or “CO” is a short hand notation for a carbonyl group, i.e., C=O.

[0084] The terms “amine” or “amino” as used herein are represented by the formula —NA1A2, where A1and A2can be, independently, hydrogen or alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. A specific example of amino is ─NH2.

[0085] The term “alkylamino” as used herein is represented by the formula —NH(-alkyl) where alkyl is a described herein. Representative examples include, but are not limited to, methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, (sec-butyl)amino group, (tert-butyl)amino group, pentylamino group, isopentylamino group, (tert-pentyl)amino group, hexylamino group, and the like.

[0086] The term “dialkylamino” as used herein is represented by the formula —N(-alkyl)2where alkyl is a described herein. Representative examples include, but are not limited to, dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di(sec-butyl)amino group, di(tert-butyl)amino group, dipentylamino group, diisopentylamino group, di(tert-pentyl)amino group, dihexylamino group, N-ethyl-N-methylamino group, N-methyl-N-propylamino group, N-ethyl-N-propylamino group and the like.

[0087] The term “carboxylic acid” as used herein is represented by the formula —C(O)OH.

[0088] The term “ester” as used herein is represented by the formula —OC(O)A1or —C(O)OA1, where A1can be alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. The term “polyester” as used herein is represented by the formula —(A1O(O)C-A2-C(O)O)a— or —(A1O(O)C-A2-OC(O))a—, where A1and A2can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein and “a” is an integer from 1 to 500. “Polyester” is as the term used to describe a group that is produced by the reaction between a compound having at least two carboxylic acid groups with a compound having at least two hydroxyl groups.

[0089] The term “ether” as used herein is represented by the formula A1OA2, where A1and A2can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein. The term “polyether” as used herein is represented by the formula —(A1O-A2O)a—, where A1and A2can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein and “a” is an integer of from 1 to 500. Examples of polyether groups include polyethylene oxide, polypropylene oxide, and polybutylene oxide.

[0090] The terms “halo,” “halogen,” or “halide,” as used herein can be used interchangeably and refer to F, Cl, Br, or I.

[0091] The terms “pseudohalide,” “pseudohalogen,” or “pseudohalo” as used herein can be used interchangeably and refer to functional groups that behave substantially similar to halides. Such functional groups include, by way of example, cyano, thiocyanato, azido, trifluoromethyl, trifluoromethoxy, perfluoroalkyl, and perfluoroalkoxy groups.

[0092] The term “heteroalkyl” as used herein refers to an alkyl group containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P and S, wherein the nitrogen, phosphorous and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. Heteroalkyls can be substituted as defined above for alkyl groups.

[0093] The term “heteroaryl,” as used herein refers to an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus, where N-oxides, sulfur oxides, and dioxides are permissible heteroatom substitutions. The heteroaryl group can be substituted or unsubstituted. The heteroaryl group can be substituted with one or more groups including, butnot limited to, alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol as described herein. Heteroaryl groups can be monocyclic, or alternatively fused ring systems. Heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, quinolinyl, isoquinolinyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, benzofuranyl, benzodioxolyl, benzothiophenyl, indolyl, indazolyl, benzimidazolyl, imidazopyridinyl, pyrazolopyridinyl, and pyrazolopyrimidinyl. Further not limiting examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, pyrazolyl, imidazolyl, benzo[d]oxazolyl, benzo[d]thiazolyl, quinolinyl, quinazolinyl, indazolyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazolyl, and pyrido[2,3-b]pyrazinyl.

[0094] The terms “heterocycle” or “heterocyclyl” as used herein can be used interchangeably and refer to single and multi-cyclic aromatic or non-aromatic ring systems in which at least one of the ring members is other than carbon. Thus, the term is inclusive of, but not limited to, “heterocycloalkyl”, “heteroaryl”, “bicyclic heterocycle” and “polycyclic heterocycle.” Heterocycle includes pyridine, pyrimidine, furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, oxazole, including, 1,2,3-oxadiazole, 1,2,5-oxadiazole and 1,3,4-oxadiazole, thiadiazole, including, 1,2,3-thiadiazole, 1,2,5-thiadiazole, and 1,3,4- thiadiazole, triazole, including, 1,2,3-triazole, 1,3,4-triazole, tetrazole, including 1,2,3,4-tetrazole and 1,2,4,5-tetrazole, pyridazine, pyrazine, triazine, including 1,2,4-triazine and 1,3,5-triazine, tetrazine, including 1,2,4,5-tetrazine, pyrrolidine, piperidine, piperazine, morpholine, azetidine, tetrahydropyran, tetrahydrofuran, dioxane, and the like. The term heterocyclyl group can also be a C2 heterocyclyl, C2-C3 heterocyclyl, C2-C4 heterocyclyl, C2-C5 heterocyclyl, C2-C6 heterocyclyl, C2-C7 heterocyclyl, C2-C8 heterocyclyl, C2-C9 heterocyclyl, C2-C10 heterocyclyl, C2-C11 heterocyclyl, and the like up to and including a C2-C18 heterocyclyl. For example, a C2 heterocyclyl comprises a group which has two carbon atoms and at least one heteroatom, including, but not limited to, aziridinyl, diazetidinyl, dihydrodiazetyl, oxiranyl, thiiranyl, and the like. Alternatively, for example, a C5 heterocyclyl comprises a group which has five carbon atoms and at least one heteroatom, including, but not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, diazepanyl, pyridinyl, and the like. It is understood that a heterocyclyl group may be bound either through a heteroatom in the ring, wherechemically possible, or one of carbons comprising the heterocyclyl ring.

[0095] The term “bicyclic heterocycle” or “bicyclic heterocyclyl” as used herein refers to a ring system in which at least one of the ring members is other than carbon. Bicyclic heterocyclyl encompasses ring systems wherein an aromatic ring is fused with another aromatic ring, or wherein an aromatic ring is fused with a non-aromatic ring. Bicyclic heterocyclyl encompasses ring systems wherein a benzene ring is fused to a 5- or a 6-membered ring containing 1, 2 or 3 ring heteroatoms or wherein a pyridine ring is fused to a 5- or a 6-membered ring containing 1, 2 or 3 ring heteroatoms. Bicyclic heterocyclic groups include, but are not limited to, indolyl, indazolyl, pyrazolo[1,5-a]pyridinyl, benzofuranyl, quinolinyl, quinoxalinyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, 3,4-dihydro-2H-chromenyl, 1H-pyrazolo[4,3-c]pyridin-3-yl; 1H- pyrrolo[3,2-b]pyridin-3-yl; and 1H-pyrazolo[3,2-b]pyridin-3-yl.

[0096] The term “heterocycloalkyl” as used herein refers to an aliphatic, partially unsaturated or fully saturated, 3- to 14-membered ring system, including single rings of 3 to 8 atoms and bi- and tricyclic ring systems. The heterocycloalkyl ring-systems include one to four heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein a nitrogen and sulfur heteroatom optionally can be oxidized and a nitrogen heteroatom optionally can be substituted. Representative heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.

[0097] The term “hydroxy” or “hydroxyl” as used herein is represented by the formula —OH.

[0098] The term “ketone” as used herein is represented by the formula A1C(O)A2, where A1and A2can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0099] The term “azide” or “azido” as used herein is represented by the formula —N3.

[0100] The term “nitro” as used herein is represented by the formula —NO2.

[0101] The term “nitrile” or “cyano” as used herein is represented by the formula —CN or —C≡N.

[0102] The term “silyl” as used herein is represented by the formula —SiA1A2A3, where A1, A2, and A3can be, independently, hydrogen or an alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0103] The term “sulfo-oxo” as used herein is represented by the formulas —S(O)A1, —S(O)2A1, —OS(O)2A1, or —OS(O)2OA1, where A1can be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. Throughout this specification “S(O)” is a short hand notation for S=O. The term “sulfonyl” is used herein to refer to the sulfo-oxo group represented by the formula —S(O)2A1, where A1can be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. The term “sulfone” as used herein is represented by the formula A1S(O)2A2, where A1and A2can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein. The term “sulfoxide” as used herein is represented by the formula A1S(O)A2, where A1and A2can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.

[0104] The term “thiol” as used herein is represented by the formula —SH.

[0105] “R1,” “R2,” “R3,” “Rn,” where n is an integer, as used herein can, independently, possess one or more of the groups listed above. For example, if R1is a straight chain alkyl group, one of the hydrogen atoms of the alkyl group can optionally be substituted with a hydroxyl group, an alkoxy group, an alkyl group, a halide, and the like. Depending upon the groups that are selected, a first group can be incorporated within second group or, alternatively, the first group can be pendant (i.e., attached) to the second group. For example, with the phrase “an alkyl group comprising an amino group,” the amino group can be incorporated within the backbone of the alkyl group. Alternatively, the amino group can be attached to the backbone of the alkyl group. The nature of the group(s) that is (are) selected will determine if the first group is embedded or attached to the second group.

[0106] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogen of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are those that result in the formation of stable or chemically feasible compounds. In is also contemplated that, in certain aspects,unless expressly indicated to the contrary, individual substituents can be further optionally substituted (i.e., further substituted or unsubstituted).

[0107] The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain aspects, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0108] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; –(CH2)0–4R°; –(CH2)0–4OR°; -O(CH2)0-4Ro, –O– (CH2)0–4C(O)OR°; –(CH2)0–4CH(OR°)2; –(CH2)0–4SR°; –(CH2)0–4Ph, which may be substituted with R°; –(CH2)0–4O(CH2)0–1Ph which may be substituted with R°; –CH=CHPh, which may be substituted with R°; –(CH2)0–4O(CH2)0–1-pyridyl which may be substituted with R°; –NO2; –CN; –N3; -(CH2)0-4N(R°)2; –(CH2)0-4N(R°)C(O)R°; –N(R°)C(S)R°; –(CH2)0–4N(R°)C(O)NR°2; -N(R°)C(S)NR°2; –(CH2)0-4N(R°)C(O)OR°; – N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; –(CH2)0-4C(O)R°; – C(S)R°; –(CH2)0-4C(O)OR°; –(CH2)0-4C(O)SR°; -(CH2)0-4C(O)OSiR°3; –(CH2)0-4OC(O)R°; – OC(O)(CH2)0-4SR–, SC(S)SR°; –(CH2)0-4SC(O)R°; –(CH2)0-4C(O)NR°2; –C(S)NR°2; – C(S)SR°; -(CH2)0-4OC(O)NR°2; -C(O)N(OR°)R°; –C(O)C(O)R°; –C(O)CH2C(O)R°; – C(NOR°)R°; -(CH2)0-4SSR°; –(CH2)0-4S(O)2R°; –(CH2)0-4S(O)2OR°; –(CH2)0-4OS(O)2R°; – S(O)2NR°2; -(CH2)0–4S(O)R°; -N(R°)S(O)2NR°2; –N(R°)S(O)2R°; –N(OR°)R°; –C(NH)NR°2; – P(O)2R°; -P(O)R°2; -OP(O)R°2; –OP(O)(OR°)2; SiR°3; –(C1–4straight or branched alkylene)O– N(R°)2; or –(C1–4straight or branched alkylene)C(O)O–N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1–6aliphatic, –CH2Ph, –O(CH2)0–1Ph, -CH2-(5-6 membered heteroaryl ring), or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0109] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, –(CH2)0–2R●, –(haloR●), –(CH2)0–2OH, –(CH2)0–2OR●, –(CH2)0–2CH(OR●)2; -O(haloR●), –CN, –N3, –(CH2)0–2C(O)R●, –(CH2)0–2C(O)OH, –(CH2)0–2C(O)OR●, – (CH2)0–2SR●, –(CH2)0–2SH, –(CH2)0–2NH2, –(CH2)0–2NHR●, –(CH2)0–2NR●2, –NO2, –SiR●3, – OSiR●3, -C(O)SR●,–(C1–4straight or branched alkylene)C(O)OR●, or –SSR●wherein each R●is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R ^ include =O and =S.

[0110] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =O, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, –O(C(R*2))2–3O–, or –S(C(R*2))2–3S–, wherein each independent occurrence of R*is selected from hydrogen, C1–6aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0– 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: –O(CR*2)2–3O–, wherein each independent occurrence of R*is selected from hydrogen, C1–6 aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0111] Suitable substituents on the aliphatic group of R*include halogen, – R●, -(haloR●), -OH, –OR●, –O(haloR●), –CN, –C(O)OH, –C(O)OR●, –NH2, –NHR●, –NR●2, or –NO2, wherein each R●is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6– membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0112] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include –R†, –NR†2, –C(O)R†, –C(O)OR†, –C(O)C(O)R†, –C(O)CH2C(O)R†, – S(O)2R†, -S(O)2NR†2, –C(S)NR†2, –C(NH)NR†2, or –N(R†)S(O)2R†; wherein each R†is independently hydrogen, C1–6 aliphatic which may be substituted as defined below, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0– 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding thedefinition above, two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0113] Suitable substituents on the aliphatic group of R†are independently halogen, – R●, -(haloR●), –OH, –OR●, –O(haloR●), –CN, –C(O)OH, –C(O)OR●, –NH2, –NHR●, –NR●2, or –NO2, wherein each R●is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1–4aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6– membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0114] The term “leaving group” refers to an atom (or a group of atoms) with electron withdrawing ability that can be displaced as a stable species, taking with it the bonding electrons. Examples of suitable leaving groups include halides and sulfonate esters, including, but not limited to, triflate, mesylate, tosylate, and brosylate.

[0115] The terms “hydrolysable group” and “hydrolysable moiety” refer to a functional group capable of undergoing hydrolysis, e.g., under basic or acidic conditions. Examples of hydrolysable residues include, without limitation, acid halides, activated carboxylic acids, and various protecting groups known in the art (see, for example, “Protective Groups in Organic Synthesis,” T. W. Greene, P. G. M. Wuts, Wiley-Interscience, 1999).

[0116] The term “organic residue” defines a carbon containing residue, i.e., a residue comprising at least one carbon atom, and includes but is not limited to the carbon-containing groups, residues, or radicals defined hereinabove. Organic residues can contain various heteroatoms, or be bonded to another molecule through a heteroatom, including oxygen, nitrogen, sulfur, phosphorus, or the like. Examples of organic residues include but are not limited alkyl or substituted alkyls, alkoxy or substituted alkoxy, mono or di-substituted amino, amide groups, etc. Organic residues can preferably comprise 1 to 18 carbon atoms, 1 to 15, carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In a further aspect, an organic residue can comprise 2 to 18 carbon atoms, 2 to 15, carbon atoms, 2 to 12 carbon atoms, 2 to 8 carbon atoms, 2 to 4 carbon atoms, or 2 to 4 carbon atoms.

[0117] A very close synonym of the term “residue” is the term “radical,” which as used in the specification and concluding claims, refers to a fragment, group, or substructure of a molecule described herein, regardless of how the molecule is prepared. For example, a 2,4-thiazolidinedione radical in a particular compound has the structure:regardless of whether thiazolidinedione is used to prepare the compound. In some embodiments the radical (for example an alkyl) can be further modified (i.e., substituted alkyl) by having bonded thereto one or more “substituent radicals.” The number of atoms in a given radical is not critical to the present invention unless it is indicated to the contrary elsewhere herein.

[0118] “Organic radicals,” as the term is defined and used herein, contain one or more carbon atoms. An organic radical can have, for example, 1-26 carbon atoms, 1-18 carbon atoms, 1-12 carbon atoms, 1-8 carbon atoms, 1-6 carbon atoms, or 1-4 carbon atoms. In a further aspect, an organic radical can have 2-26 carbon atoms, 2-18 carbon atoms, 2-12 carbon atoms, 2- 8 carbon atoms, 2-6 carbon atoms, or 2-4 carbon atoms. Organic radicals often have hydrogen bound to at least some of the carbon atoms of the organic radical. One example, of an organic radical that comprises no inorganic atoms is a 5, 6, 7, 8-tetrahydro-2-naphthyl radical. In some embodiments, an organic radical can contain 1-10 inorganic heteroatoms bound thereto or therein, including halogens, oxygen, sulfur, nitrogen, phosphorus, and the like. Examples of organic radicals include but are not limited to an alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, mono-substituted amino, di-substituted amino, acyloxy, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, haloalkoxy, aryl, substituted aryl, heteroaryl, heterocyclic, or substituted heterocyclic radicals, wherein the terms are defined elsewhere herein. A few non-limiting examples of organic radicals that include heteroatoms include alkoxy radicals, trifluoromethoxy radicals, acetoxy radicals, dimethylamino radicals and the like.

[0119] “Inorganic radicals,” as the term is defined and used herein, contain no carbon atoms and therefore comprise only atoms other than carbon. Inorganic radicals comprise bonded combinations of atoms selected from hydrogen, nitrogen, oxygen, silicon, phosphorus, sulfur, selenium, and halogens such as fluorine, chlorine, bromine, and iodine, which can be present individually or bonded together in their chemically stable combinations. Inorganic radicals have10 or fewer, or preferably one to six or one to four inorganic atoms as listed above bonded together. Examples of inorganic radicals include, but not limited to, amino, hydroxy, halogens, nitro, thiol, sulfate, phosphate, and like commonly known inorganic radicals. The inorganic radicals do not have bonded therein the metallic elements of the periodic table (such as the alkali metals, alkaline earth metals, transition metals, lanthanide metals, or actinide metals), although such metal ions can sometimes serve as a pharmaceutically acceptable cation for anionic inorganic radicals such as a sulfate, phosphate, or like anionic inorganic radical. Inorganic radicals do not comprise metalloids elements such as boron, aluminum, gallium, germanium, arsenic, tin, lead, or tellurium, or the noble gas elements, unless otherwise specifically indicated elsewhere herein.

[0120] Compounds described herein can contain one or more double bonds and, thus, potentially give rise to cis / trans (E / Z) isomers, as well as other conformational isomers. Unless stated to the contrary, the invention includes all such possible isomers, as well as mixtures of such isomers.

[0121] Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer and diastereomer, and a mixture of isomers, such as a racemic or scalemic mixture. Compounds described herein can contain one or more asymmetric centers and, thus, potentially give rise to diastereomers and optical isomers. Unless stated to the contrary, the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. Mixtures of stereoisomers, as well as isolated specific stereoisomers, are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

[0122] Many organic compounds exist in optically active forms having the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, thesecompounds, called stereoisomers, are identical except that they are non-superimposable mirror images of one another. A specific stereoisomer can also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture. Many of the compounds described herein can have one or more chiral centers and therefore can exist in different enantiomeric forms. If desired, a chiral carbon can be designated with an asterisk (*). When bonds to the chiral carbon are depicted as straight lines in the disclosed formulas, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the formula. As is used in the art, when it is desired to specify the absolute configuration about a chiral carbon, one of the bonds to the chiral carbon can be depicted as a wedge (bonds to atoms above the plane) and the other can be depicted as a series or wedge of short parallel lines is (bonds to atoms below the plane). The Cahn-Ingold-Prelog system can be used to assign the (R) or (S) configuration to a chiral carbon.

[0123] Compounds described herein comprise atoms in both their natural isotopic abundance and in non-natural abundance. The disclosed compounds can be isotopically-labeled or isotopically-substituted compounds identical to those described, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as2H,3H,13C,14C,15N,18O,17O,35S,18F and36Cl, respectively. Compounds further comprise prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as3H and14C are incorporated, are useful in drug and / or substrate tissue distribution assays. Tritiated, i.e.,3H, and carbon-14, i.e.,14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e.,2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the procedures below, by substituting a readilyavailable isotopically labeled reagent for a non- isotopically labeled reagent.

[0124] The compounds described in the invention can be present as a solvate. In some cases, the solvent used to prepare the solvate is an aqueous solution, and the solvate is then often referred to as a hydrate. The compounds can be present as a hydrate, which can be obtained, for example, by crystallization from a solvent or from aqueous solution. In this connection, one, two, three or any arbitrary number of solvent or water molecules can combine with the compounds according to the invention to form solvates and hydrates. Unless stated to the contrary, the invention includes all such possible solvates.

[0125] The term “co-crystal” means a physical association of two or more molecules which owe their stability through non-covalent interaction. One or more components of this molecular complex provide a stable framework in the crystalline lattice. In certain instances, the guest molecules are incorporated in the crystalline lattice as anhydrates or solvates, see e.g. “Crystal Engineering of the Composition of Pharmaceutical Phases. Do Pharmaceutical Co-crystals Represent a New Path to Improved Medicines?” Almarasson, O., et. al., The Royal Society of Chemistry, 1889-1896, 2004. Examples of co-crystals include p-toluenesulfonic acid and benzenesulfonic acid.

[0126] It is also appreciated that certain compounds described herein can be present as an equilibrium of tautomers. For example, ketones with an α-hydrogen can exist in an equilibrium of the keto form and the enol form.

[0127] Likewise, amides with an N-hydrogen can exist in an equilibrium of the amide form and the imidic acid form. As another example, pyrazoles can exist in two tautomeric forms, N1- unsubstituted, 3-A3and N1-unsubstituted, 5-A3as shown below.

[0128] Unless stated to the contrary, the invention includes all such possible tautomers.

[0129] It is known that chemical substances form solids, which are present in different states of order which are termed polymorphic forms or modifications. The different modifications of a polymorphic substance can differ greatly in their physical properties. The compounds according to the invention can be present in different polymorphic forms, with it being possible for particular modifications to be metastable. Unless stated to the contrary, the invention includes all such possible polymorphic forms.

[0130] In some aspects, a structure of a compound can be represented by a formula:which is understood to be equivalent to a formula:wherein n is typically an integer. That is, Rnis understood to represent five independent substituents, Rn(a), Rn(b), Rn(c), Rn(d), Rn(e). By “independent substituents,” it is meant that each R substituent can be independently defined. For example, if in one instance Rn(a)is halogen, then Rn(b)is not necessarily halogen in that instance.

[0131] Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art. For example, the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, Pa.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and supplemental volumes (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); March’s Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition); and Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989).

[0132] Unless otherwise expressly stated, it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not actually recite an order to be followed by its steps or it is not otherwise specifically stated in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including: matters of logic with respect to arrangement of steps or operational flow; plain meaning derived from grammatical organization or punctuation; and the number or type of embodiments described in the specification.

[0133] Disclosed are the components to be used to prepare the compositions of the invention as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the methods of the invention.

[0134] It is understood that the compositions disclosed herein have certain functions. Disclosed herein are certain structural requirements for performing the disclosed functions, and it is understood that there are a variety of structures that can perform the same function that are related to the disclosed structures, and that these structures will typically achieve the same result.B. COMPOUNDS

[0135] In one aspect, the invention relates to compounds that inhibit Nox4 signaling. The disclosed compounds can be useful in, for example, the treatment of fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis), or acute respiratory distress syndrome (ARDS).

[0136] It is contemplated that each disclosed derivative can be optionally further substituted. It is also contemplated that any one or more derivative can be optionally omitted from the invention. It is understood that a disclosed compound can be provided by the disclosed methods. It is also understood that the disclosed compounds can be employed in the disclosed methods of using. 1. STRUCTURE

[0137] In one aspect, disclosed are compounds having a structure represented by a formula:wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:wherein * denotes a bond connected to:and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: A is ‒C(O)‒; or L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when either: n is 1; oris a double bond, Q1is ‒N=, and Q2is ‒CH=, and R3is ‒NR12aR12b, then R12ais hydrogen or C1-C4 alkyl.

[0138] In one aspect, disclosed are compounds having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl,C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0139] In one aspect, disclosed are compounds having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, orwherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from: , , wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, andis substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

[0140] In one aspect, disclosed are compounds selected from:or a pharmaceutically acceptable salt thereof.

[0141] In one aspect, disclosed are compounds selected from:,or a pharmaceutically acceptable salt thereof.

[0142] In one aspect, disclosed are compounds having a structure represented by a formula:, wherein q is 1 or 2; wherein each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1- C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein each of R6aand R6bis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R6aand R6btogether comprise =O; and wherein R7is selected from hydrogen and C1-C4 alkyl; and wherein R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2(C1-C4 alkyl), ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒ SO2Cy2; wherein each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3; and wherein Cy3, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl; and wherein Cy2, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, C6-C14 aryl,and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3; wherein r is 0, 1, or 2; and wherein Ar3, when present, is selected from C6 aryl and C2-C5 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4; wherein each of R14aand R14b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy5; and wherein Cy5, when present, is selected from a C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Cy4, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

[0143] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0144] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0145] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0146] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0147] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0148] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0149] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0150] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0151] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0152] In various aspects, the compound has a structure represented by a formula:,or a pharmaceutically acceptable salt thereof.

[0153] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0154] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0155] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0156] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0157] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0158] In various aspects, the compound has a structure represented by a formula:, wherein each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

[0159] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0160] In various aspects, the compound has a structure represented by a formula:, wherein L is a structure selected from: ,,or a pharmaceutically acceptable salt thereof.

[0161] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0162] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0163] In various aspects, the compound has a structure represented by a formula selected from:or a pharmaceutically acceptable salt thereof.

[0164] In various aspects, the compound has a structure represented by a formula selected from:,or a pharmaceutically acceptable salt thereof.

[0165] In various aspects, the compound is selected from:, , or a pharmaceutically acceptable salt thereof.

[0166] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0167] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0168] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0169] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0170] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0171] In various aspects, the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

[0172] In various aspects, the compound is selected from:,,,or a pharmaceutically acceptable salt thereof.

[0173] In various aspects, the compound is selected from:,or a pharmaceutically acceptable salt thereof. is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒nd, Q1is ‒N=, and Q2is ‒CH=.

[0175] In various aspects,is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒ C(O)‒. In a further aspect,is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒. In a still further aspect, single bond, Q1is ‒CH2‒, and Q2is ‒C(O)‒.

[0176] In various aspects,is a double bond, Q1is ‒N=, and Q2is ‒CH=.

[0177] In one aspect, m is 1 or 2. In a further aspect, m is 1. In a still further aspect, m is 2.

[0178] In one aspect, n is 0 or 1. In a further aspect, n is 0. In a still further aspect, n is 1.

[0179] In one aspect, o is selected from 0, 1, and 2. In a further aspect, o is selected from 0 and 1. In a still further aspect, o is selected from 0 and 2. In a yet further aspect, o is selected from 1 and 2. In an even further aspect, o is 0. In an even still further aspect, o is 1. In an even yet further aspect, o is 2.

[0180] In one aspect, q is 1 or 2. In a further aspect, q is 1. In a still further aspect, q is 2.

[0181] In one aspect, r is 0, 1, or 2. In a further aspect, r is 0 or 1. In a yet further aspect, r is0 or 2. In a still further aspect, r is 1 or 2. In an even further aspect, r is 0. In an even yet further aspect, r is 1. In an even still further aspect, r is 2. a. A GROUP

[0182] In one aspect, A is selected from ‒C(O)‒ and ‒SO2‒. In a further aspect, A is ‒ C(O)‒. In a yet further aspect, A is ‒SO2‒. b. L GROUP

[0183] In one aspect, L is ‒(CR11aR11b)2‒ or a structure selected from: ,,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒.

[0184] In various aspects, L is ‒(CR11aR11b)2‒ . In a further aspect, L is ‒(CR11aR11b)(CH2)‒.

[0185] In various aspects, L is a structure selected from:,

[0186] In various aspects, L is a structure selected from: ,,

[0187] In various aspects, L is a structure selected from: ,

[0188] In various aspects, L is a structure:.

[0189] In various aspects, L is a structure selected from:c. Q1AND Q2GROUPS

[0190] In one aspect, Q1is ‒CR10aR10b‒ and Q2is ‒CR10cR10d‒ or ‒C(O)‒, or Q1is ‒N= and Q2is ‒CH=.

[0191] In various aspects, Q1is ‒CR10aR10b‒ and Q2is ‒CR10cR10d‒ or ‒C(O)‒. In a further aspect, Q1is ‒CR10aR10b‒ and Q2is ‒CR10cR10d‒. In a still further aspect, Q1is ‒CH2‒ and Q2is ‒CR10cR10d‒. In yet a further aspect, Q1is ‒CR10aR10b‒ and Q2is ‒C(O)‒. In an even further aspect, Q1is ‒CH2‒ and Q2is ‒C(O)‒.

[0192] In various aspects, Q1is ‒N= and Q2is ‒CH=.

[0193] In various aspects, Q1is ‒CH2‒.

[0194] In various aspects, Q2is ‒CH=. d. R1A, R1B, R1C, AND R1DGROUPS

[0195] In one aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, ethyl, n- propyl, isopropyl, ethenyl, propenyl, isopropenyl, −CH2F, −CH2CH2F, −CH2CH2CH2F, −CH(CH3)CH2F, −CH2Cl, −CH2CH2Cl, −CH2CH2CH2Cl, −CH(CH3)CH2Cl, −CH2CN, −CH2CH2CN, −CH2CH2CH2CN, −CH(CH3)CH2CN, −CH2OH, −CH2CH2OH, −CH2CH2CH2OH, −CH(CH3)CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH2CH2F, −OCH2CH2CH2F, −OCH(CH3)CH2F, −OCH3, −OCH2CH3, −OCH2CH2CH3, −OCH(CH3)2, −NHCH3, −NHCH2CH3, −NHCH2CH2CH3, −NHCH(CH3)2, −N(CH3)2, −N(CH3)CH2CH3, −N(CH3)CH2CH2CH3, −N(CH3)CH(CH3)2, −CH2NH2, −CH2CH2NH2, −CH2CH2CH2NH2, and −CH(CH3)CH2NH2. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, ethyl, ethenyl, −CH2F, −CH2CH2F, −CH2Cl, −CH2CH2Cl, −CH2CN, −CH2CH2CN, −CH2OH, −CH2CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH2CH2F, −OCH3, −OCH2CH3, −NHCH3, −NHCH2CH3, −N(CH3)2, −N(CH3)CH2CH3, −CH2NH2, and −CH2CH2NH2. In yet a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl,−CH2F, −CH2Cl, −CH2CN, −CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH3, −NHCH3, −N(CH3)2, and −CH2NH2.

[0196] In various aspects, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, and C2-C4 alkenyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, – CN, –OH, ‒NO2, methyl, ethyl, n-propyl, i-propyl, ethenyl, propenyl, and isopropenyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, – NH2, –CN, –OH, ‒NO2, methyl, ethyl, and ethenyl. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, and methyl.

[0197] In various aspects, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, C1-C4 alkyl, and C1-C4 alkoxy. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, ‒CN, methyl, ethyl, n-propyl, i- propyl, –OCH3, –OCH2CH3, –OCH2CH2CH3, and –OCH(CH3)CH3. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, ‒CN, methyl, ethyl, –OCH3, and –OCH2CH3. In yet a further aspect, each of R1a, R1b, R1c, and R1dis independently selected hydrogen, –F, –Cl, ‒CN, methyl, and –OCH3.

[0198] In various aspects, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen and C1-C4 alkyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, methyl, ethyl, n-propyl, and i-propyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, methyl, and ethyl. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen and methyl.

[0199] In various aspects, each of R1a, R1b, R1c, and R1dis independently C1-C4 alkyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from methyl, ethyl, n- propyl, and i-propyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from methyl and ethyl. In a still further aspect, each of R1a, R1b, R1c, and R1dis methyl.

[0200] In various aspects, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 haloalkyl, and C1-C4 cyanoalkyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, – NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, –CH2CH2F, –CH2CH2Cl, –CH2CH2CH2F, – CH2CH2CH2Cl, –CH(CH3)CH2F, –CH(CH3)CH2Cl, –CH2CN, –CH2CH2CN, –CH2CH2CH2CN, and –CH(CH3)CH2CN. In a further aspect, each of R1a, R1b, R1c, and R1dis independentlyselected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, –CH2CH2F, – CH2CH2Cl, –CH2CN, and –CH2CH2CN. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, and – CH2CN.

[0201] In various aspects, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, and C1- C4 alkoxy. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2OH, –CH2CH2OH, –CH2CH2CH2OH, – CH(CH3)CH2OH, –OCF3, –OCH2CF3, –OCH2CH2CF3, –OCH(CH3)CF3, –OCH3, –OCH2CH3, – OCH2CH2CH3, and –OCH(CH3)CH3. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2OH, – CH2CH2OH, –OCF3, –OCH2CF3, –OCH3, and –OCH2CH3. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, – CH2OH, –OCF3, –OCH2CF3, and –OCH3.

[0202] In various aspects, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, –NHCH2CH3, – NHCH2CH2CH3, –NHCH(CH3)CH3, –N(CH3)2, –N(CH2CH3)2, –N(CH2CH2CH3)2, – N(CH(CH3)CH3)2, –N(CH3)(CH2CH3), –CH2NH2, –CH2CH2NH2, –CH2CH2CH2NH2, and – CH(CH3)CH2NH2. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, –NHCH2CH3, –N(CH3)2, – N(CH2CH3)2, –N(CH3)(CH2CH3), –CH2NH2, and –CH2CH2NH2. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒ NO2, –NHCH3, –N(CH3)2, and –CH2NH2.

[0203] In various aspects, each of R1a, R1b, R1c, and R1d isindependently selected from hydrogen and halogen. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, –F, and –Cl. In a further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen and –Cl. In a still further aspect, each of R1a, R1b, R1c, and R1dis independently selected from hydrogen and –F.

[0204] In various aspects, each of R1a, R1b, R1c, and R1dis hydrogen.e. R2GROUPS

[0205] In one aspect, R2, when present, is selected from hydrogen and C1-C4 alkyl. In a further aspect, R2, when present, is selected from hydrogen, methyl, ethyl, propyl, and isopropyl. In a yet further aspect, R2, when present, is selected from hydrogen, methyl, and ethyl. In a still further aspect, R2, when present, is selected from hydrogen and methyl.

[0206] In various aspect, R2, when present, is C1-C4 alkyl. In a further aspect, R2, when present, is selected from methyl, ethyl, propyl, and isopropyl. In a yet further aspect, R2, when present, is selected from methyl and ethyl. In a still further aspect, R2, when present, is methyl.

[0207] In various aspects, R2, when present, is hydrogen. f. R3GROUPS

[0208] In one aspect, R3is selected from ‒NR12aR12band Ar1. In a further aspect, R3is ‒ NR12aR12b. In a still further aspect, R3is Ar1. g. R5A, R5B, R5C, AND R5DGROUPS

[0209] In one aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, ethyl, n-propyl, isopropyl, ethenyl, propenyl, isopropenyl, −CH2F, −CH2CH2F, −CH2CH2CH2F, −CH(CH3)CH2F, −CH2Cl, −CH2CH2Cl, −CH2CH2CH2Cl, −CH(CH3)CH2Cl, −CH2CN, −CH2CH2CN, −CH2CH2CH2CN, −CH(CH3)CH2CN, −CH2OH, −CH2CH2OH, −CH2CH2CH2OH, −CH(CH3)CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH2CH2F, −OCH2CH2CH2F, −OCH(CH3)CH2F, −OCH3, −OCH2CH3, −OCH2CH2CH3, −OCH(CH3)2, −NHCH3, −NHCH2CH3, −NHCH2CH2CH3, −NHCH(CH3)2, −N(CH3)2, −N(CH3)CH2CH3, −N(CH3)CH2CH2CH3, −N(CH3)CH(CH3)2, −CH2NH2, −CH2CH2NH2, −CH2CH2CH2NH2, and −CH(CH3)CH2NH2. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, ethyl, ethenyl, −CH2F, −CH2CH2F, −CH2Cl, −CH2CH2Cl, −CH2CN, −CH2CH2CN, −CH2OH, −CH2CH2OH, −OCF3,−OCHF3, −OCH2F, −OCH2CH2F, −OCH3, −OCH2CH3, −NHCH3, −NHCH2CH3, −N(CH3)2, −N(CH3)CH2CH3, −CH2NH2, and −CH2CH2NH2. In yet a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, −CH2F, −CH2Cl, −CH2CN, −CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH3, −NHCH3, −N(CH3)2, and −CH2NH2.

[0210] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, and C2-C4 alkenyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, – CN, –OH, ‒NO2, methyl, ethyl, n-propyl, i-propyl, ethenyl, propenyl, and isopropenyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, – NH2, –CN, –OH, ‒NO2, methyl, ethyl, and ethenyl. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, and methyl.

[0211] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, C1-C4 alkyl, and C1-C4 alkoxy. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, ‒CN, methyl, ethyl, n-propyl, i- propyl, –OCH3, –OCH2CH3, –OCH2CH2CH3, and –OCH(CH3)CH3. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, ‒CN, methyl, ethyl, –OCH3, and –OCH2CH3. In yet a further aspect, each of R5a, R5b, R5c, and R5dis independently selected hydrogen, –F, –Cl, ‒CN, methyl, and –OCH3.

[0212] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen and C1-C4 alkyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, methyl, ethyl, n-propyl, and i-propyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, methyl, and ethyl. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen and methyl.

[0213] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 haloalkyl, and C1-C4 cyanoalkyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, – NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, –CH2CH2F, –CH2CH2Cl, –CH2CH2CH2F, – CH2CH2CH2Cl, –CH(CH3)CH2F, –CH(CH3)CH2Cl, –CH2CN, –CH2CH2CN, –CH2CH2CH2CN, and –CH(CH3)CH2CN. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, –CH2CH2F, –CH2CH2Cl, –CH2CN, and –CH2CH2CN. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, and – CH2CN.

[0214] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, and C1- C4 alkoxy. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2OH, –CH2CH2OH, –CH2CH2CH2OH, – CH(CH3)CH2OH, –OCF3, –OCH2CF3, –OCH2CH2CF3, –OCH(CH3)CF3, –OCH3, –OCH2CH3, – OCH2CH2CH3, and –OCH(CH3)CH3. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2OH, – CH2CH2OH, –OCF3, –OCH2CF3, –OCH3, and –OCH2CH3. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, – CH2OH, –OCF3, –OCH2CF3, and –OCH3.

[0215] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, –NHCH2CH3, – NHCH2CH2CH3, –NHCH(CH3)CH3, –N(CH3)2, –N(CH2CH3)2, –N(CH2CH2CH3)2, – N(CH(CH3)CH3)2, –N(CH3)(CH2CH3), –CH2NH2, –CH2CH2NH2, –CH2CH2CH2NH2, and – CH(CH3)CH2NH2. In a further aspect, each of R5a, R5b, R5c, and R5dindependently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, –NHCH2CH3, –N(CH3)2, –N(CH2CH3)2, –N(CH3)(CH2CH3), –CH2NH2, and –CH2CH2NH2. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, – N(CH3)2, and –CH2NH2.

[0216] In various aspects, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen and halogen. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, –F, and –Cl. In a further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen and –Cl. In a still further aspect, each of R5a, R5b, R5c, and R5dis independently selected from hydrogen and –F.

[0217] In various aspects, at least two of R5a, R5b, R5c, and R5dis hydrogen.

[0218] In various aspects, at least three of R5a, R5b, R5c, and R5dis hydrogen.

[0219] In various aspects, each of R5a, R5b, R5c, and R5dis hydrogen. h. R6AAND R6BGROUPS

[0220] In one aspect, each of R6aand R6bis independently selected from hydrogen and C1- C4 alkyl, or each of R6aand R6btogether comprise =O.

[0221] In various aspects, each of R6aand R6bis independently selected from hydrogen and C1-C4 alkyl. In a further aspect, each of R6aand R6bis independently selected from hydrogen, methyl, ethyl, propyl, and isopropyl. In a yet further aspect, each of R6aand R6bis independently selected from hydrogen, methyl, and ethyl. In a still further aspect, each of R6aand R6bis independently selected from hydrogen and methyl.

[0222] In various aspects, each of R6aand R6bis independently selected C1-C4 alkyl. In a further aspect, each of R6aand R6bis independently selected from methyl, ethyl, propyl, and isopropyl. In a yet further aspect, each of R6aand R6bis independently selected from methyl, and ethyl. In a still further aspect, each of R6aand R6bis methyl.

[0223] In various aspect, each of R6aand R6bis hydrogen.

[0224] In various aspects, each of R6aand R6btogether comprise =O. i. R7AND R8GROUPS

[0225] In one aspect, R7is selected from hydrogen and C1-C4 alkyl and R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2(C1-C4 alkyl), ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒ SO2Cy2; or each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4.

[0226] In various aspects, R7is selected from hydrogen and C1-C4 alkyl and R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒SO2Cy2.

[0227] In various aspects, R7is selected from hydrogen and C1-C4 alkyl. In a further aspect, R7is selected from hydrogen, methyl, ethyl, propyl, and isopropyl. In a yet further aspect, R7is selected from hydrogen, methyl, and ethyl. In a still further aspect, R7is selected from hydrogen and methyl.

[0228] In various aspects, R7is C1-C4 alkyl. In a further aspect, R7is selected from methyl, ethyl, propyl, and isopropyl. In a yet further aspect, R7is selected from methyl and ethyl. In astill further aspect, R7is methyl.

[0229] In various aspects, R7is hydrogen.

[0230] In various aspects, R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒ SO2(C1-C4 alkyl), ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒SO2Cy2. In a further aspect, R8is selected from hydrogen, methyl, ethyl, propyl, isopropyl, ‒C(O)NR13aR13b, ‒SO2CH3, ‒SO2CH2CH3, ‒ SO2CH2CH2CH3, ‒SO2NR13aR13b, ‒C(O)Cy2, and ‒SO2Cy2. In a yet further aspect, R8is selected from hydrogen, methyl, ethyl, ‒C(O)NR13aR13b, ‒SO2CH3, ‒SO2CH2CH3, ‒ SO2NR13aR13b, ‒C(O)Cy2, and ‒SO2Cy2.

[0231] In various aspects, R8is ‒SO2NR13aR13b. In a further aspect, one of R13aand R13bis hydrogen and the other is Cy3. In a yet further aspect, each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl. In a still further aspect, each of R13aand R13btogether comprise an unsubstituted C4-C5 heterocycloalkyl.

[0232] In various aspects, R8is ‒SO2Cy2.

[0233] In various aspects, each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4. In a further aspect, each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4. In a still further aspect, each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 groups selected from ‒SO2NR14aR14band ‒SO2Cy4.

[0234] In various aspects, each of R7and R8together comprise a C2-C5 heterocycloalkyl selected from piperidinyl, morpholinyl, and tetrahydropyranyl, and are substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4. In a further aspect, each of R7and R8together comprise a C2-C5 heterocycloalkyl selected from piperidinyl, morpholinyl, and tetrahydropyranyl, and are substituted with 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4. In a still further aspect, each of R7and R8together comprise a C2-C5 heterocycloalkyl selected from piperidinyl, morpholinyl, and tetrahydropyranyl, and are substituted with 0 groups selected from ‒SO2NR14aR14band ‒SO2Cy4. j. R10A, R10B, R10C, AND R10DGROUPS

[0235] In one aspect, each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or each of R10cand R10dtogether comprise =O.

[0236] In various aspects, each of R10a, R10b, R10c, and R10dis independently selected fromhydrogen and C1-C4 alkyl. In a further aspect, each of R10a, R10b, R10c, and R10dis independently selected from hydrogen, methyl, ethyl, n-propyl, and i-propyl. In a yet further aspect, each of R10a, R10b, R10c, and R10dis independently selected from hydrogen, methyl, and ethyl. In a still further aspect, each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and methyl.

[0237] In various aspects, each of R10a, R10b, R10c, and R10dis independently C1-C4 alkyl. In a further aspect, each of R10a, R10b, R10c, and R10dis independently selected from methyl, ethyl, n- propyl, and i-propyl. In a yet further aspect, each of R10a, R10b, R10c, and R10dis independently selected from methyl and ethyl. In a still further aspect, each of R10a, R10b, R10c, and R10dis methyl.

[0238] In various aspects, each of R10a, R10b, R10c, and R10dis hydrogen.

[0239] In various aspects, each of R10cand R10dtogether comprise =O. k. R11AAND R11BGROUPS

[0240] In one aspect, each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or each of R11aand R11btogether comprise =O.

[0241] In various aspects, each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl. In a further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, methyl, ethyl, n-propyl, i-propyl, ‒CH2F, ‒ CH2CH2F, ‒CH2CH2CH2F, ‒CH(CH3)CH2F, ‒CH2Cl, ‒CH2CH2Cl, ‒CH2CH2CH2Cl, and ‒ CH(CH3)CH2Cl. In a yet further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, methyl, ethyl, ‒CH2F, ‒CH2CH2F, ‒CH2Cl, and ‒CH2CH2Cl. In a still further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, methyl, ‒CH2F, and ‒CH2Cl.

[0242] In various aspects, each occurrence of R11aand R11bis independently selected from hydrogen and C1-C4 alkyl. In a further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, methyl, ethyl, n-propyl, and i-propyl. In a yet further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, methyl, and ethyl. In a still further aspect, each occurrence of R11aand R11bis independently selected from hydrogen and methyl.

[0243] In various aspects, each occurrence of R11aand R11bis independently C1-C4 alkyl. Ina further aspect, each occurrence of R11aand R11bis independently selected from methyl, ethyl, n-propyl, and i-propyl. In a yet further aspect, each occurrence of R11aand R11bis independently selected from methyl and ethyl. In a still further aspect, each occurrence of R11aand R11bis methyl.

[0244] In various aspects, each occurrence of R11aand R11bis independently selected from hydrogen and C1-C4 haloalkyl. In a further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, ‒CH2F, ‒CH2CH2F, ‒CH2CH2CH2F, ‒CH(CH3)CH2F, ‒ CH2Cl, ‒CH2CH2Cl, ‒CH2CH2CH2Cl, and ‒CH(CH3)CH2Cl. In a yet further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, ‒CH2F, ‒CH2CH2F, ‒ CH2Cl, and ‒CH2CH2Cl. In a still further aspect, each occurrence of R11aand R11bis independently selected from hydrogen, ‒CH2F, and ‒CH2Cl.

[0245] In various aspects, each occurrence of R11aand R11bis hydrogen.

[0246] In various aspects, one of R11aand R11bis hydrogen and one of R11aand R11bis selected from C1-C4 alkyl and C1-C4 haloalkyl. In a further aspect, one of R11aand R11bis hydrogen and one of R11aand R11bis selected from methyl, ethyl, n-propyl, i-propyl, ‒CH2F, ‒ CH2CH2F, ‒CH2CH2CH2F, ‒CH(CH3)CH2F, ‒CH2Cl, ‒CH2CH2Cl, ‒CH2CH2CH2Cl, and ‒ CH(CH3)CH2Cl. In a yet further aspect, one of R11aand R11bis hydrogen and one of R11aand R11bis selected from methyl, ethyl, ‒CH2F, ‒CH2CH2F, ‒CH2Cl, and ‒CH2CH2Cl. In a still further aspect, one of R11aand R11bis hydrogen and one of R11aand R11bis selected from methyl, ‒CH2F, and ‒CH2Cl.

[0247] In various aspects, one of R11aand R11bis hydrogen and one of R11aand R11bis C1-C4 alkyl. In a further aspect, one of R11aand R11bis hydrogen and one of R11aand R11bis selected from methyl, ethyl, n-propyl, and i-propyl. In a yet further aspect, one of R11aand R11bis hydrogen and one of R11aand R11bis selected from methyl and ethyl. In an even further aspect, one of R11aand R11bis hydrogen and one of R11aand R11bis methyl.

[0248] In various aspects, each of R11aand R11btogether comprise =O. l. R12AAND R12BGROUPS

[0249] In one aspect, R12ais selected from hydrogen, C1-C4 alkyl, and Ar2, and R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3, or each of R12aand R12btogether comprise a C2- C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

[0250] In various aspects, R12ais selected from hydrogen, C1-C4 alkyl, and Ar2, and R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3.

[0251] In various aspects, each of R12aand R12bis independently C1-C4 alkyl. In a further aspect, each of R12aand R12bis independently selected from methyl, ethyl, n-propyl, and isopropyl. In a still further aspect, each of R12aand R12bis independently selected from methyl and ethyl. In yet a further aspect, each of R12aand R12bis methyl.

[0252] In various aspects, R12ais selected from hydrogen, C1-C4 alkyl, and Ar2. In a further aspect, R12ais selected from hydrogen, methyl, ethyl, propyl, isopropyl, and Ar2. In a further aspect, R12ais selected from hydrogen, methyl, ethyl, and Ar2. In a still further aspect, R12ais selected from hydrogen, methyl, and Ar2.

[0253] In various aspects, R12ais C1-C4 alkyl. In a further aspect, R12ais selected from methyl, ethyl, propyl, and isopropyl. In a further aspect, R12ais selected from methyl and ethyl. In a still further aspect, R12ais methyl.

[0254] In various aspects, R12ais Ar2.

[0255] In various aspects, R12ais hydrogen.

[0256] In various aspects, R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3. In a further aspect, R12bis selected from methyl, ethyl, propyl, isopropyl, ‒CH2Ar3, and Ar3. In a further aspect, R12bis selected from methyl, ethyl, ‒CH2Ar3, and Ar3. In a still further aspect, R12bis selected from methyl, ‒CH2Ar3, and Ar3.

[0257] In various aspects, R12bis C1-C4 alkyl. In a further aspect, R12bis selected from methyl, ethyl, propyl, and isopropyl. In a further aspect, R12bis selected from methyl and ethyl. In a still further aspect, R12bis methyl.

[0258] In various aspects, R12bis selected from ‒CH2Ar3and Ar3. In a further aspect, R12bis Ar3. In a still further aspect, R12bis ‒CH2Ar3.

[0259] In various aspects, each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4aminoalkyl. In a further aspect, each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even still further aspect, each of R12aand R12btogether comprise an unsubstituted C2-C5 heterocycloalkyl.

[0260] In various aspects, each of R12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, each of R12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is substituted with 0 or 1 groupy selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, each of R12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even still further aspect, each ofR12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is unsubstituted. m. R13AAND R13BGROUPS

[0261] In one aspect, each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3, or each of R13aand R13btogether comprise an unsubstituted C2- C5 heterocycloalkyl.

[0262] In various aspects, each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3. In a further aspect, each of R13aand R13b, when present, is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, and Cy3. In a still further aspect, each of R13aand R13b, when present, is independently selected from hydrogen, methyl, ethyl, and Cy3. In a yet further aspect, each of R13aand R13b, when present, is independently selected from hydrogen, methyl, and Cy3.

[0263] In various aspects, one of R13aand R13b, when present, is hydrogen and the other is Cy3.

[0264] In various aspects, R13aand R13b, when present, together comprise an unsubstituted C2-C5 heterocycloalkyl.

[0265] In various aspect, R13aand R13b, when present, together comprise an unsubstituted C4-C5 heterocycloalkyl. n. R14AAND R14BGROUPS

[0266] In one aspect, each of R14aand R14b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy5. In various aspects, each of R14aand R14b, when present, is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, and Cy5. In a still further aspect, each of R14aand R14b, when present, is independently selected from hydrogen, methyl, ethyl, and Cy5. In a yet further aspect, each of R14aand R14b, when present, is independently selected from hydrogen, methyl, and Cy5.

[0267] In various aspects, each of R14aand R14b, when present, is independently selected from hydrogen and C1-C4 alkyl. In various aspects, each of R14aand R14b, when present, is independently selected from hydrogen, methyl, ethyl, propyl, and isopropyl. In a still further aspect, each of R14aand R14b, when present, is independently selected from hydrogen, methyl,and ethyl. In a yet further aspect, each of R14aand R14b, when present, is independently selected from hydrogen and methyl.

[0268] In various aspects, each of R14aand R14b, when present, is independently C1-C4 alkyl. In various aspects, each of R14aand R14b, when present, is independently selected from methyl, ethyl, propyl, and isopropyl. In a still further aspect, each of R14aand R14b, when present, is independently selected from methyl and ethyl. In a yet further aspect, each of R14aand R14b, when present, is methyl.

[0269] In various aspects, each of R14aand R14b, when present, is independently selected from hydrogen and Cy5. In a further aspect, each of R14aand R14b, when present, is Cy5. In a still further aspect, each of R14aand R14b, when present, is hydrogen. o. R20A, R20B, R20C, R20D, AND R20EGROUPS

[0270] In one aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1- C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, ethyl, n-propyl, isopropyl, ethenyl, propenyl, isopropenyl, −CH2F, −CH2CH2F, −CH2CH2CH2F, −CH(CH3)CH2F, −CH2Cl, −CH2CH2Cl, −CH2CH2CH2Cl, −CH(CH3)CH2Cl, −CH2CN, −CH2CH2CN, −CH2CH2CH2CN, −CH(CH3)CH2CN, −CH2OH, −CH2CH2OH, −CH2CH2CH2OH, −CH(CH3)CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH2CH2F, −OCH2CH2CH2F, −OCH(CH3)CH2F, −OCH3, −OCH2CH3, −OCH2CH2CH3, −OCH(CH3)2, −NHCH3, −NHCH2CH3, −NHCH2CH2CH3, −NHCH(CH3)2, −N(CH3)2, −N(CH3)CH2CH3, −N(CH3)CH2CH2CH3, −N(CH3)CH(CH3)2, −CH2NH2, −CH2CH2NH2, −CH2CH2CH2NH2, and −CH(CH3)CH2NH2. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, methyl, ethyl, ethenyl, −CH2F, −CH2CH2F, −CH2Cl, −CH2CH2Cl, −CH2CN, −CH2CH2CN, −CH2OH, −CH2CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH2CH2F, −OCH3, −OCH2CH3, −NHCH3, −NHCH2CH3, −N(CH3)2, −N(CH3)CH2CH3, −CH2NH2, and −CH2CH2NH2. In yet a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, methyl, −CH2F, −CH2Cl, −CH2CN, −CH2OH, −OCF3, −OCHF3, −OCH2F, −OCH3,−NHCH3, −N(CH3)2, and −CH2NH2.

[0271] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, and C2-C4 alkenyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, methyl, ethyl, n-propyl, i-propyl, ethenyl, propenyl, and isopropenyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, methyl, ethyl, and ethenyl. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, – CN, –OH, ‒NO2, and methyl.

[0272] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, C1-C4 alkyl, and C1-C4 alkoxy. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, ‒CN, methyl, ethyl, n-propyl, i-propyl, –OCH3, –OCH2CH3, –OCH2CH2CH3, and –OCH(CH3)CH3. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, ‒CN, methyl, ethyl, –OCH3, and –OCH2CH3. In yet a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected hydrogen, –F, –Cl, ‒CN, methyl, and –OCH3.

[0273] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen and C1-C4 alkyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, methyl, ethyl, n-propyl, and i-propyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, methyl, and ethyl. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen and methyl.

[0274] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 haloalkyl, and C1-C4 cyanoalkyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, – F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, –CH2CH2F, –CH2CH2Cl, –CH2CH2CH2F, – CH2CH2CH2Cl, –CH(CH3)CH2F, –CH(CH3)CH2Cl, –CH2CN, –CH2CH2CN, –CH2CH2CH2CN, and –CH(CH3)CH2CN. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2F, –CH2Cl, – CH2CH2F, –CH2CH2Cl, –CH2CN, and –CH2CH2CN. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2,–CH2F, –CH2Cl, and –CH2CN.

[0275] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, and C1-C4 alkoxy. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2OH, –CH2CH2OH, – CH2CH2CH2OH, –CH(CH3)CH2OH, –OCF3, –OCH2CF3, –OCH2CH2CF3, –OCH(CH3)CF3, – OCH3, –OCH2CH3, –OCH2CH2CH3, and –OCH(CH3)CH3. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒ NO2, –CH2OH, –CH2CH2OH, –OCF3, –OCH2CF3, –OCH3, and –OCH2CH3. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –CH2OH, –OCF3, –OCH2CF3, and –OCH3.

[0276] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, – NHCH2CH3, –NHCH2CH2CH3, –NHCH(CH3)CH3, –N(CH3)2, –N(CH2CH3)2, – N(CH2CH2CH3)2, –N(CH(CH3)CH3)2, –N(CH3)(CH2CH3), –CH2NH2, –CH2CH2NH2, – CH2CH2CH2NH2, and –CH(CH3)CH2NH2. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, – NHCH2CH3, –N(CH3)2, –N(CH2CH3)2, –N(CH3)(CH2CH3), –CH2NH2, and –CH2CH2NH2. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, –Cl, –NH2, –CN, –OH, ‒NO2, –NHCH3, –N(CH3)2, and –CH2NH2.

[0277] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen and halogen. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, –F, and –Cl. In a further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen and –Cl. In a still further aspect, each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen and –F.

[0278] In various aspects, each of R20a, R20b, R20c, R20d, and R20eis hydrogen. p. AR1GROUPS

[0279] In one aspect, Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and issubstituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a further aspect, Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0280] In various aspects, Ar1is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Ar1is C6-C14 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar1is C6-C14 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy,C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar1is C6-C14 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒ C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar1is an unsubstituted C6-C14 aryl.

[0281] In various aspects, Ar1is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1. In a further aspect, Ar1is C6 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar1is C6 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar1is C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar1is an unsubstituted C6 aryl.

[0282] In various aspects, Ar1is C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole,benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Ar1is C2-C10 heteroaryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1. In a still further aspect, Ar1is C2-C10 heteroaryl substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar1is C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar1is an unsubstituted C2-C10 heteroaryl. q. AR2GROUPS

[0283] In one aspect, Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar2is selected from C6-C14aryl and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1. In an even further aspect, Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0284] In various aspects, Ar2is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Ar2is C6-C14 aryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar2is C6-C14 aryl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1. In a yet further aspect, Ar2is C6-C14 aryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar2is an unsubstituted C6-C14 aryl.

[0285] In various aspects, Ar2is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1. In a further aspect, Ar2is C6 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar2is C6 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar2is C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar2is an unsubstituted C6 aryl.

[0286] In various aspects, Ar2is a C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. Examples of C2-C10 heteroaryl include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Ar2is a C2-C10 heteroaryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1. In a still further aspect, Ar2is a C2-C10 heteroaryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar2is a C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar2is an unsubstituted C2- C10 heteroaryl. r. AR3GROUPS

[0287] In one aspect, Ar3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Ar3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Ar3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In yet a further aspect, Ar3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Ar3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0288] In various aspects, Ar3, when present, is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Ar3, when present, is C6-C14 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Ar3, when present, is C6-C14 arylsubstituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In yet a further aspect, Ar3, when present, is C6-C14 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Ar3, when present, is an unsubstituted C6-C14 aryl.

[0289] In various aspects, Ar3, when present, is C6-aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Ar3, when present, is a C6-aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Ar3, when present, is a C6-aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In yet a further aspect, Ar3, when present, is a C6-aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Ar3, when present, is an unsubstituted C6-aryl.

[0290] In various aspects, Ar3, when present, is a C6-aryl substituted with a ‒CF3group.

[0291] In various aspects, Ar3, when present, is a C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine,pyrimidine, and pyrazine. In a further aspect, Ar3, when present, is a C2-C10 heteroaryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Ar3, when present, is a C2-C10 heteroaryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In yet a further aspect, Ar3, when present, is a C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Ar3, when present, is an unsubstituted C2-C10 heteroaryl.

[0292] In various aspects, Ar3, when present, is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Ar3, when present, is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Ar3, when present, is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In yet a further aspect, Ar3, when present, is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Ar3, when present, is selected from an unsubstituted pyrazolyl, an unsubstituted pyridinyl, and anunsubstituted pyrimidinyl.

[0293] In various aspects, Ar3, when present, is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with a ‒CF3group. In a further aspect, Ar3, when present, is pyrazolyl, and is substituted with a ‒CF3group. In a yet further aspect, Ar3, when present, is pyridinyl, and is substituted with a ‒CF3group. In a yet further aspect, Ar3, when present, is pyrimidinyl, and is substituted with a ‒CF3group. a. CY1GROUPS

[0294] In one aspect, Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a still further aspect, Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is unsubstituted.

[0295] In various aspects, Cy1is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a further aspect, Cy1is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a still further aspect, Cy1is selected from C3- C6 cycloalkyl and C3-C6 heterocycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is unsubstituted.

[0296] In various aspects, Cy1is C3-C6 cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. Examples of C3-C6 cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[3.1.0]hexane, and spiro[2.3]hexane. In a further aspect, Cy1is C3-C6 cycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is C3-C6 cycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a still further aspect, Cy1is C3-C6 cycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is anunsubstituted C3-C6 cycloalkyl.

[0297] In various aspects, Cy1is C3-C6 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. Examples of C3- C6 heterocycloalkyls include, but are not limited to, thiirane, oxirane, aziridine, thietane, azetidine, oxetane, pyrrolidine, imidazolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, piperazine, thiane, and morpholine. In a further aspect, Cy1is C3-C6 heterocycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is C3-C6 heterocycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a still further aspect, Cy1is C3-C6 heterocycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is an unsubstituted C3-C6 heterocycloalkyl.

[0298] In various aspects, Cy1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a further aspect, Cy1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4aminoalkyl. In a still further aspect, Cy1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0299] In various aspects, Cy1is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Cy1is C6-C14 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is C6-C14 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a still further aspect, Cy1is C6-C14 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is an unsubstituted C6-C14 aryl.

[0300] In various aspects, Ar1is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒ OCy1, and ‒NH(CH2)oCy1. In a further aspect, Ar1is C6 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a still further aspect, Ar1is C6 aryl substituted with0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In a yet further aspect, Ar1is C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1. In an even further aspect, Ar1is an unsubstituted C6 aryl.

[0301] In various aspects, Cy1is C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Cy1is C2-C10 heteroaryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a yet further aspect, Cy1is C2-C10 heteroaryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In a still further aspect, Cy1is C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl. In an even further aspect, Cy1is an unsubstituted C2-C10 heteroaryl. b. CY2GROUPS

[0302] In one aspect, Cy2, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a still further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is monosubstituted with a groups selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In an even further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is unsubstituted.

[0303] In various aspects, Cy2, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl and C3- C6 heterocycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a still further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In an even further aspect, Cy2, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is unsubstituted.

[0304] In various aspects, Cy2, when present, is C3-C6 cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. Examples of C3-C6 cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[3.1.0]hexane, and spiro[2.3]hexane. In a further aspect, Cy2, when present, is C3-C6 cycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is C3-C6 cycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a still further aspect, Cy2, when present, is C3-C6 cycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In an even further aspect, Cy2, when present, is an unsubstituted C3-C6 cycloalkyl.

[0305] In various aspects, Cy2, when present, is C3-C6 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒ C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. Examples of C3-C6 heterocycloalkyls include, but are not limited to, thiirane, oxirane, aziridine, thietane, azetidine, oxetane, pyrrolidine, imidazolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, piperazine, thiane, and morpholine. In a further aspect, Cy2, when present, is C3-C6 heterocycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is C3-C6 heterocycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a still further aspect, Cy2, when present, is C3-C6 heterocycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In an even further aspect, Cy2, when present, is an unsubstituted C3-C6 heterocycloalkyl.

[0306] In various aspects, Cy2, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a further aspect, Cy2, when present, is selected from C6-C14 aryl and C2-C10heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is selected from C6-C14 aryl and C2- C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a still further aspect, Cy2, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In an even further aspect, Cy2, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0307] In various aspects, Cy2, when present, is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Cy2, when present, is C6-C14 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is C6-C14 aryl substituted with 0 or 1 group selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In a still further aspect, Cy2, when present, is C6-C14 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In an even further aspect, Cy2, when present, is an unsubstituted C6-C14 aryl.

[0308] In various aspects, Cy2, when present, is C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr3, and ‒NH(CH2)rAr3.

[0309] In various aspects, Cy2, when present, is C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Cy2, when present, is C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a yet further aspect, Cy2, when present, is C2-C10 heteroaryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3. In a still further aspect, Cy2, when present, is C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒ NH(CH2)rAr3. In an even further aspect, Cy2, when present, is an unsubstituted C2-C10 heteroaryl.c. CY3GROUPS

[0310] In one aspect, Cy3, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy3, when present,is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl, C3- C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is unsubstituted.

[0311] In various aspects, Cy3, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is unsubstituted.

[0312] In various aspects, Cy3, when present, is C3-C6 cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C3-C6 cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[3.1.0]hexane, and spiro[2.3]hexane. In a further aspect, Cy3, when present, is C3-C6 cycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is C3-C6 cycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is C3-C6 cycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is an unsubstituted C3-C6 cycloalkyl.

[0313] In various aspects, Cy3, when present, is C3-C6 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl,C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C3-C6 heterocycloalkyls include, but are not limited to, thiirane, oxirane, aziridine, thietane, azetidine, oxetane, pyrrolidine, imidazolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, piperazine, thiane, and morpholine. In a further aspect, Cy3, when present, is C3-C6 heterocycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is C3-C6 heterocycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is C3-C6 heterocycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is an unsubstituted C3-C6 heterocycloalkyl.

[0314] In various aspects, Cy3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is monosubstituted with agroup selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0315] In various aspects, Cy3, when present, is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Cy3, when present, is C6-C14 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is C6-C14 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is C6-C14 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is an unsubstituted C6-C14 aryl.

[0316] In various aspects, Cy3is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy3is C6 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3is C6 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3is C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3is an unsubstituted C6 aryl.

[0317] In various aspects, Cy3, when present, is C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Cy3, when present, is C2-C10 heteroaryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy3, when present, is C2-C10 heteroaryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy3, when present, is C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy3, when present, is an unsubstituted C2-C10 heteroaryl. d. CY4GROUPS

[0318] In one aspect, Cy4, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a furtheraspect, Cy4, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl, C3- C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is unsubstituted.

[0319] In various aspects, Cy4, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is unsubstituted.

[0320] In various aspects, Cy4, when present, is C3-C6 cycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C3-C6 cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[3.1.0]hexane, and spiro[2.3]hexane. In a further aspect, Cy4, when present, is C3-C6 cycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is C3-C6 cycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is C3-C6 cycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is an unsubstituted C3-C6 cycloalkyl.

[0321] In various aspects, Cy4, when present, is C3-C6 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C3-C6 heterocycloalkyls include, but are not limited to, thiirane, oxirane, aziridine, thietane, azetidine, oxetane, pyrrolidine, imidazolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, piperazine, thiane, and morpholine. In a further aspect, Cy4, when present, is C3-C6 heterocycloalkyl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is C3-C6 heterocycloalkyl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is C3-C6 heterocycloalkyl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is an unsubstituted C3-C6 heterocycloalkyl.

[0322] In various aspects, Cy4, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy4, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is selected from C6-C14 aryl and C2-C10 heteroaryl, and is unsubstituted.

[0323] In various aspects, Cy4, when present, is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Cy4, when present, is C6-C14 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is C6-C14 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is C6-C14 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is an unsubstituted C6-C14 aryl.

[0324] In various aspects, Cy4is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy4is C6 aryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4is C6 aryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4is C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4is an unsubstituted C6 aryl.

[0325] In various aspects, Cy4, when present, is C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Cy4, when present, is a C2-C10 heteroaryl substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy4, when present, is C2-C10 heteroaryl substituted with 0 or 1 group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy4, when present, is C2-C10 heteroaryl monosubstituted with a group selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy4, when present, is an unsubstituted C2-C10 heteroaryl. e. CY5GROUPS

[0326] In one aspect, Cy5, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl, C3- C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is monosubstituted with a groups selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is unsubstituted.

[0327] In various aspects, Cy5, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is substituted with 0 or 1 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is monosubstituted with a groups selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is selected from C3-C6 cycloalkyl and C3-C6 heterocycloalkyl, and is unsubstituted.

[0328] In various aspects, Cy5, when present, is selected from C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy5, when present, is selected from C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5, when present, is selected from C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is selected from C6-C14 aryl, and C2-C10 heteroaryl, and is monosubstituted with a groups selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is selected from C6-C14 aryl, and C2-C10 heteroaryl, and is unsubstituted.

[0329] In various aspects, Cy5, when present, is C3-C6 cycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy5, when present, is C3-C6 cycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5, when present, is C3-C6 cycloalkyl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is C3-C6 cycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4)dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is an unsubstituted C3-C6 cycloalkyl.

[0330] In various aspects, Cy5, when present, is C3-C6 heterocycloalkyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy , when present, is C3-C6 heterocycloalkyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5, when present, is C3-C6 heterocycloalkyl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is C3-C6 heterocycloalkyl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1- C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is an unsubstituted C3-C6 heterocycloalkyl.

[0331] In various aspects, Cy5, when present, is C6-C14 aryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C6-C14 aryls include, but are not limited to, phenyl and naphthyl. In a further aspect, Cy5, when present, is C6-C14 aryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5, when present, is C6-C14 aryl, and is substituted with 0 or 1 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4)dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is a C6-C14 aryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1- C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is an unsubstituted C6-C14 aryl.

[0332] In various aspects, Cy5is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a further aspect, Cy5is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5is C6 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5is C6 aryl monosubstituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5is an unsubstituted C6 aryl.

[0333] In various aspects, Cy5, when present, is C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. Examples of C2-C10 heteroaryls include, but are not limited to, oxazole, oxadiazole, indole, indazole, isoindole, pyrazole, triazole, benzothiazole, benzoxazole, quinolone, isoquinoline, pyridine, pyrimidine, and pyrazine. In a further aspect, Cy5, when present, is C2-C10 heteroaryl, and is substituted with 0, 1, or 2 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a yet further aspect, Cy5, when present, is C2-C10 heteroaryl, and is substitutedwith 0 or 1 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In a still further aspect, Cy5, when present, is C2-C10 heteroaryl, and is monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl. In an even further aspect, Cy5, when present, is an unsubstituted C2-C10 heteroaryl. 2. EXEMPLARY COMPOUNDS

[0334] In one aspect, a compound can be present as one or more of the following structures: ,,, , or a pharmaceutically acceptable salt thereof.

[0335] In one aspect, a compound can be present as the following structure:,or a pharmaceutically acceptable salt thereof.

[0336] In one aspect, a compound can be present as the following structure:,,,,   or a pharmaceutically acceptable salt thereof.

[0337] It is contemplated that one or more compounds can optionally be omitted from the disclosed invention.

[0338] It is understood that the disclosed compounds can be used in connection with the disclosed methods, compositions, kits, and uses.

[0339] It is understood that pharmaceutical acceptable derivatives of the disclosed compounds can be used also in connection with the disclosed methods, compositions, kits, and uses. The pharmaceutical acceptable derivatives of the compounds can include any suitable derivative, such as pharmaceutically acceptable salts as discussed below, isomers, radiolabeled analogs, tautomers, and the like. C. METHODS OF MAKING A COMPOUND

[0340] The compounds of this invention can be prepared by employing reactions as shown in the following schemes, in addition to other standard manipulations that are known in the literature, exemplified in the experimental sections or clear to one skilled in the art. For clarity, examples having a single substituent are shown where multiple substituents are allowed under the definitions disclosed herein.

[0341] Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in the following Reaction Schemes, as described and exemplified below. In certain specific examples, the disclosed compounds can be prepared by Routes I-III, as described and exemplified below. The following examples are provided so that the invention might be more fully understood, are illustrative only, and should not be construed as limiting.1. ROUTE I

[0342] In one aspect, the disclosed compounds can be prepared as shown below. SCHEME 1A.

[0343] Compounds are represented in generic form, wherein X is a halide and with other substituents as noted in compound descriptions elsewhere herein. A specific non-limiting example of the synthesis shown in Scheme 1A is provided below. SCHEME 1B.

[0344] In one aspect, compounds of type 1.6, and similar compounds, can be prepared according to reaction Scheme 1B above. Thus, compounds of type 1.6 can be prepared by a coupling reaction between an appropriate amine, e.g.1.4 as shown above, and an appropriate acyl or sulfonyl halide, e.g., 1.5 as shown above. Appropriate amines, appropriate acyl halides, and appropriate sulfonyl halides are commercially available or prepared by methods known to one of skill in the art. The coupling reaction is carried out in the presence of an appropriate base, e.g., triethylamine, in an appropriate solvent, e.g., dichloromethane (DCM), at an appropriate temperature, e.g., room temperature, for an appropriate period of time, e.g., 4 hours. As can beappreciated by one skilled in the art the above reaction provides an example of a generalized approach wherein compounds similar in structure to the specific reactions above (compounds similar to 1.1 and 1.2) can be substituted in the reaction to provide compounds similar to Formula 1.3. 2. ROUTE II

[0345] In one aspect, the disclosed compounds can be prepared as shown below. SCHEME 2A.

[0346] Compounds are represented in generic form, with substituents as noted in compound descriptions elsewhere herein. A specific non-limiting example of the synthesis shown in Scheme 2A is provided below. SCHEME 2B.

[0347] In one aspect, compounds of type 2.6, and similar compounds, can be prepared according to reaction Scheme 2B above. Thus, compounds of type 2.6 can be prepared by a reductive amination of an appropriate amine, e.g.2.4 as shown above. The reductive amination iscarried out in the presence of an appropriate aldehyde, e.g., 2.5 as shown above, an appropriate reducing agent, e.g., sodium triacetoxyborohydride, and an appropriate acid, e.g., acetic acid, in an appropriate solvent, e.g.¸1,2-dichloroethane. Appropriate amines and appropriate aldehydes are commercially available or prepared by methods known to one of skill in the art. As can be appreciated by one skilled in the art the above reaction provides an example of a generalized approach wherein compounds similar in structure to the specific reactions above (compounds similar to 2.1 and 2.2) can be substituted in the reaction to provide compounds similar to Formula 2.3. 3. ROUTE III

[0348] In one aspect, the disclosed compounds can be prepared as shown below. SCHEME 3A.

[0349] Compounds are represented in generic form, wherein X is a halide and with other substituents as noted in compound descriptions elsewhere herein. A specific non-limiting example of the synthesis shown in Scheme 3A is provided below. SCHEME 3B.

[0350] In one aspect, compounds of type 3.6, and similar compounds, can be prepared according to reaction Scheme 3B above. Thus, compounds of type 3.6 can be prepared by a coupling reaction between an appropriate amine, e.g.3.4 as shown above, and an appropriate aryl halide, e.g., 3.5 as shown above. Appropriate amines and appropriate aryl halides are commercially available or prepared by methods known to one of skill in the art. The coupling reaction is carried out in the presence of an appropriate catalyst, e.g., tris(dibenzylideneacetone)dipalladium (0), an appropriate ligand, e.g., Xantphos, and an appropriate base, e.g., sodium tertbutoxide, in an appropriate solvent, e.g., 1.4-dioxane. As can be appreciated by one skilled in the art the above reaction provides an example of a generalized approach wherein compounds similar in structure to the specific reactions above (compounds similar to 3.1 and 3.2) can be substituted in the reaction to provide compounds similar to Formula 3.3. D. PHARMACEUTICAL COMPOSITIONS

[0351] In one aspect, disclosed are pharmaceutical compositions comprising an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0352] Thus, in one aspect, disclosed are pharmaceutical compositions comprising an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from: , , wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1,is a single bond, Q1is ‒CH2‒, and Q2is ‒ CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1-C4 alkyl.

[0353] In one aspect, disclosed are pharmaceutical compositions comprising an effective amount of a compound selected from:, ,   ,  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0354] In one aspect, disclosed are pharmaceutical compositions comprising an effective amount of a compound selected from:,    , ,  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0355] In various aspects, the compounds and compositions of the invention can be administered in pharmaceutical compositions, which are formulated according to the intended method of administration. The compounds and compositions described herein can be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. For example, a pharmaceutical composition can be formulated for local or systemic administration, e.g., administration by drops or injection into the ear, insufflation (such as into the ear), intravenous, topical, or oral administration.

[0356] The nature of the pharmaceutical compositions for administration is dependent on the mode of administration and can readily be determined by one of ordinary skill in the art. In various aspects, the pharmaceutical composition is sterile or sterilizable. The therapeutic compositions featured in the invention can contain carriers or excipients, many of which are known to skilled artisans. Excipients that can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, polypeptides (for example, serum albumin), EDTA, sodiumchloride, liposomes, mannitol, sorbitol, water, and glycerol. The nucleic acids, polypeptides, small molecules, and other modulatory compounds featured in the invention can be administered by any standard route of administration. For example, administration can be parenteral, intravenous, subcutaneous, or oral. A modulatory compound can be formulated in various ways, according to the corresponding route of administration. For example, liquid solutions can be made for administration by drops into the ear, for injection, or for ingestion; gels or powders can be made for ingestion or topical application. Methods for making such formulations are well known and can be found in, for example, Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA 1990.

[0357] In various aspects, the disclosed pharmaceutical compositions comprise the disclosed compounds (including pharmaceutically acceptable salt(s) thereof) as an active ingredient, a pharmaceutically acceptable carrier, and, optionally, other therapeutic ingredients or adjuvants. The instant compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

[0358] In various aspects, the pharmaceutical compositions of this invention can include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of the compounds of the invention. The compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

[0359] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[0360] In preparing the compositions for oral dosage form, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystallinecellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by standard aqueous or nonaqueous techniques

[0361] A tablet containing the composition of this invention can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets can be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.

[0362] The pharmaceutical compositions of the present invention comprise a compound of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants. The instant compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

[0363] Pharmaceutical compositions of the present invention suitable for parenteral administration can be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

[0364] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating actionof microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

[0365] Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, mouth washes, gargles, and the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations can be prepared, utilizing a compound of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.

[0366] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above can include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of the invention, and / or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.

[0367] In a further aspect, an effective amount is a therapeutically effective amount. In a still further aspect, an effective amount is a prophylactically effective amount.

[0368] In a further aspect, the pharmaceutical composition is administered to a mammal. In a still further aspect, the mammal is a human. In an even further aspect, the human is a patient.

[0369] In a further aspect, the pharmaceutical composition is used to treat a disorder associated with over-activation of NOX4 signaling. In a still further aspect, the pharmaceutical composition is used to treat a disorder that is a fibrotic disorder or acute respiratory distress syndrome (ARDS). In a yet further aspect, the fibrotic disorder is pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, or scleroderma or systemic sclerosis.

[0370] It is understood that the disclosed compositions can be prepared from the disclosed compounds. It is also understood that the disclosed compositions can be employed in the disclosed methods of using.E. METHODS OF INHIBITING NADPH OXIDASE 4 (NOX4) SIGNALING IN A CELL

[0371] In various aspects, the compounds and compositions disclosed herein are useful for inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell.

[0372] Thus, in one aspect, disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell, the method comprising contacting the cell with an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:  , wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0373] In one aspect, disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell, the method comprising contacting the cell with an effective amount of a compound selected from:or a pharmaceutically acceptable salt thereof.

[0374] In various aspects, the cell is mammalian.

[0375] In various aspects, the cell is a human.

[0376] In various aspects, the cell has been isolated from a mammal prior to the contacting step.

[0377] In various aspects, contacting is ex vivo.

[0378] In various aspects, contacting is in vitro.

[0379] In various aspects, contacting is via administration to a mammal. In a further aspect, the mammal has been diagnosed with a need for inhibiting NOX4 signaling prior to the administering step. In a further aspect, the mammal has been diagnosed with a need for treatment of a disorder associated with over-activation of NOX4 signaling prior to the administering step. In a yet further aspect, the disorder is a fibrotic disorder or acute respiratory distress syndrome (ARDS). In a still further aspect, the mammal has been diagnosed with a need for inhibition of NOX4 signaling prior to the administering step. F. METHODS OF INHIBITING NADPH OXIDASE 4 (NOX4) SIGNALING IN A SUBJECT

[0380] In one aspect, disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.

[0381] Thus, in one aspect, disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; whereinis a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from: , wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl,C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0382] In one aspect, disclosed are methods of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject, the method comprising administering to the subject an effective amount of a compound selected from:  ,  or a pharmaceutically acceptable salt thereof..

[0383] In various aspects, the subject is a mammal.

[0384] In various aspects, the subject is a human.

[0385] In various aspects, the subject has been diagnosed with a need for inhibiting NOX4 signaling to the administering step.

[0386] In various aspects, the method further comprises identifying a subject in need of inhibition of NOX4 signaling as further described herein. G. METHODS OF TREATING A FIBROTIC DISORDER IN A SUBJECT

[0387] In one aspect, disclosed are methods of treating a fibrotic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof. The reactive oxygen species (ROS)- generating enzyme, NADPH oxidase (Nox4), is a critical mediator of myofibroblast functions and Nox4 expression is elevated in the lungs of patients with IPF and in IPF lung fibroblasts.

[0388] Thus, in one aspect, disclosed are methods of treating a fibrotic disorder in a subject, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from: , , wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6- C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino,(C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6-C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒ (CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1, is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1- C4 alkyl.

[0389] In one aspect, disclosed are methods of treating a fibrotic disorder in a subject, the method comprising administering to the subject an effective amount of a compound having a compound selected from:, or a pharmaceutically acceptable salt thereof. Examples of fibrotic disorders include, but are not limited to, pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, or scleroderma or systemic sclerosis.

[0390] In various aspects, the fibrotic disorder is pulmonary fibrosis. In a further aspect, the pulmonary fibrosis is idiopathic pulmonary fibrosis.

[0391] In various aspects, the subject is a mammal.

[0392] In various aspects, the subject is a human.

[0393] In various aspects, the subject has been diagnosed with the fibrotic disorder prior to the administering step.

[0394] In various aspects, the method further comprises the step of identifying a subject in need of treatment of the fibrotic disorder.

[0395] In various aspects, the method further comprises administering to the subject an anti- fibrotic agent. Examples of anti-fibrotic agents include, but are not limited to, nintedanib and pirfenidone. H. METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN A SUBJECT

[0396] In one aspect, disclosed are methods treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a disclosed compound, or a pharmaceutically acceptable salt thereof. Oxidative stress has been implicated as a major contributor to the pathogenesis of ARDS. In addition, aged mice with severe ARDS exhibited sustained upregulation of Nox4 and elevated ROS levels. As such, strategies that block the source of ROS production are more specific and effective in comparison to antioxidant strategies because the damage from highly reactive ROS molecules occur rapidly.

[0397] Pulmonary endothelial cells (ECs) line the surface of the lung vasculature and are a critical regulator of vascular homeostasis. Located at the interface between the bloodstream and lung tissue, the endothelium serves as a barrier that regulates the influx of inflammatory cells and fluid into the interstitial space. A key pathological feature of ARDS is EC barrier disruption, which results in increased vascular permeability and inflammatory influx. The accumulation of inflammatory cells and protein-rich fluid into the alveolar space can result in alveolar filling, hypoxemia, and ultimately respiratory failure. Autopsy reports from COVID-19 patients revealed severe injury to lung ECs accompanied by significant inflammatory cell influx, and transcriptomics are consistent with EC dysregulation. Thus, it is theorized that a successful treatment for ARDS and COVID-19-associated ARDS would combat EC barrier dysfunction and inflammatory injury to circumvent pulmonary edema and reduce the risk of respiratory failure and death.

[0398] Further, as noted above, a substantial body of evidence has implicated oxidative stress as a major contributor to the pathogenesis of ARDS. Numerous studies have demonstrated high levels of ROS in the lungs following acute lung injury (ALI) in animal models and in ARDS patients. Excessive ROS production has been shown to promote EC barrier dysfunction and increased vascular permeability, which amplifies tissue damage, capillary leak, and pulmonaryedema. Elevated ROS levels in ARDS patients have also been linked to increased oxidatively modified proteins, which perpetuate barrier dysfunction and inflammation leading to lung injury. ARDS patients with greater levels of oxidative molecular damage have increased mortality rates; thus, minimizing oxidative stress is a promising approach to mitigate lung damage and improve survival. Unfortunately, despite the well-recognized role of oxidative stress in ARDS pathogenesis, the mechanisms that drive ARDS-associated redox imbalance are largely unknown. Thus, the ability to precisely target key mediators of this process has proved challenging. Moreover, although studies evaluating the effectiveness of antioxidants in animal models of ALI have been promising, clinical trials with antioxidant therapies have failed to reduce ARDS mortality. One potential explanation is that while antioxidants function to scavenge existing ROS (that has already been produced), they do not block the source of ROS production. Oxidants are highly reactive molecules, and once generated, can rapidly induce damage to cells and surrounding tissues and induce inflammatory responses. Thus, strategies that directly block the source of ROS production are likely to be more specific and effective in comparison to antioxidant strategies because the damage from highly reactive ROS molecules may occur rapidly. The proposed treatment method seeks to develop a therapeutic, which targets the critical pathological features of ARDS: excessive ROS production, barrier dysfunction, and inflammatory injury.

[0399] As life expectancy continues to increase, there is a demographic shift toward a growing elderly population, including the U.S. elderly veteran population. ARDS disproportionately affects the elderly population; higher incidence and mortality are associated with advancing age. ARDS incidence is 16 / 100,000 persons for adolescents (15-19 years) vs. 306 / 100,000 among the elderly (75-84 years). ARDS mortality increases with age; 24% in adolescents vs.60% in elderly. ARDS mortality is 2-fold higher in patients >70 years vs. under 70, and elderly survivors have more difficulties recovering. Older age is also a significant risk factor for COVID-19-associated hospitalization, including the development of ARDS and progression from ARDS to death; 75% of hospitalized COVID-19 patients were ≥50 years. Of those who required intensive care, mechanical ventilation, or died, the median age was 63. COVID-19 mortality rate is also highly correlated to older age: 42% (80-89 years), 32% (70-79), 8% (60-69), and 2% (50-59). Impor...

Claims

CLAIMS What is claimed is:

1. A compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or whereindouble bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,,,wherein * denotes a bond connected to:, and wherein ** denotes a bond connected to ‒(NR2)n‒; wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl,or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when either: (a) n is 1; or (b) is a double bond, Q1is ‒N=, and Q2is ‒CH=, and R3is ‒NR12aR12b, then R12ais hydrogen or C1-C4 alkyl.

2. The compound of claim 1, wherein n is 0.

3. The compound of claim 1, wherein n is 1.

4. The compound of any one of claims 1 to 3, wherein m is 1.

5. The compound of any one of claims 1 to 3, wherein m is 2.

6. The compound of any one of claims 1 to 5, wherein is a single bond, Q1is ‒ CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; 7. The compound of any one of claims 1 to 5, wherein is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒.

8. The compound of any one of claims 1 to 5, wherein is a single bond, Q1is ‒CH2‒, and Q2is ‒C(O)‒.

9. The compound of any one of claims 1 to 5, wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=.

10. The compound of any one of claims 1 to 9, wherein A is ‒SO2‒.

11. The compound of any one of claims 1 to 10, wherein L is ‒(CR11aR11b)2‒.

12. The compound of any one of claims 1 to 10, wherein L is ‒(CR11aR11b)(CH2)‒.

13. The compound of claim 12, wherein each of R11aand R11bis hydrogen.

14. The compound of claim 12, wherein one of R11aand R11bis hydrogen and one of R11aand R11bis selected from C1-C4 alkyl and C1-C4 haloalkyl.

15. The compound of claim 12, wherein one of R11aand R11bis hydrogen and one of R11aand R11bis methyl.

16. The compound of claim 12, wherein each of R11aand R11btogether comprise =O.

17. The compound of claim 1, wherein L is a structure selected from: ,,18. The compound of any one of claims 1 to 17, wherein each of R1a, R1b, R1c, and R1dis hydrogen.

19. The compound of any one of claims 1 to 18, wherein R2, when present, is hydrogen.

20. The compound of any one of claims 1 to 19, wherein R3is ‒NR12aR12b.

21. The compound of claim 20, wherein each of R12aand R12bis C1-C4 alkyl.

22. The compound of claim 20, wherein R12ais hydrogen.

23. The compound of claim 20, wherein R12bis Ar3.

24. The compound of claim 23, wherein Ar3is C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

25. The compound of claim 23, wherein Ar3is C6-aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1- C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

26. The compound of claim 23, wherein Ar3is a C6-aryl substituted with a ‒CF3group.

27. The compound of claim 23, wherein Ar3is a C2-C10 heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

28. The compound of claim 27, wherein Ar3is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

29. The compound of claim 27, wherein Ar3is selected from pyrazolyl, pyridinyl, and pyrimidinyl, and is substituted with a ‒CF3group.

30. The compound of claim 20, wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

31. The compound of claim 20, wherein each of R12aand R12btogether comprise a unsubstituted C2-C5 heterocycloalkyl.

32. The compound of claim 20, wherein each of R12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl.

33. The compound of claim 20, wherein each of R12aand R12btogether comprise a pyrrolidinyl or a piperidinyl, and is unsubstituted.

34. The compound of any one of claims 1 to 33, wherein R3is Ar1.

35. The compound of claim 1, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

36. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

37. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

38. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

39. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

40. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

41. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

42. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

43. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

44. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

45. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

46. The compound of claim 35, wherein the compound has a structure represented by a formula:,or a pharmaceutically acceptable salt thereof.

47. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

48. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

49. The compound of claim 35, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

50. The compound of claim 35, wherein the compound has a structure represented by a formula:, wherein each of R20a, R20b, R20c, R20d, and R20eis independently selected from hydrogen, halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1- C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

51. The compound of claim 50, wherein the compound has a structure represented by a formula:,or a pharmaceutically acceptable salt thereof.

52. The compound of claim 1, wherein the compound has a structure represented by a formula: ,,or a pharmaceutically acceptable salt thereof.

53. The compound of claim 52, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

54. The compound of claim 52, wherein the compound has a structure represented by a formula:, or a pharmaceutically acceptable salt thereof.

55. The compound of claim 52, wherein the compound has a structure represented by a formula selected from:or a pharmaceutically acceptable salt thereof.

56. The compound of claim 52, wherein the compound has a structure represented by a formula selected from:,or a pharmaceutically acceptable salt thereof.

57. The compound of claim 1, wherein the compound is selected from:, , , or a pharmaceutically acceptable salt thereof.

58. A pharmaceutical composition comprising an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein is a single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3;wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or(b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1,is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1-C4 alkyl.

59. A method of inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell, the method comprising contacting the cell with an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or whereindouble bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3;wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or(b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1,is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1-C4 alkyl.

60. The method of claim 59, wherein the cell is mammalian.

61. The method of claim 59, wherein the cell is human.

62. The method of any one of claims 59 to 61, wherein the cell has been isolated from a mammal prior to the contacting step.

63. The method of any one of claims 59 to 62, wherein the contacting is ex vivo.

64. The method of any one of claims 59 to 62, wherein the contacting is in vitro.

65. The method of any one of claims 59 to 64, wherein contacting is via administration to a mammal.

66. The method of claim 65, wherein the mammal has been diagnosed with a need for inhibiting NOX4 signaling prior to the administering step.

67. The method of claim 65, wherein the mammal has been diagnosed with a need for treatment of a disorder associated with over-activation of NOX4 signaling prior to the administering step.

68. The method of claim 67, wherein the disorder is a fibrotic disorder or acute respiratory distress syndrome (ARDS).

69. The method of claim 65, wherein the mammal has been diagnosed with a need for inhibition of NOX4 signaling prior to the administering step.

70. A method of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or whereindouble bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,,,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl,or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1,is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1-C4 alkyl.

71. The method of claim 70, wherein the subject is a mammal.

72. The method of claim 70, wherein the subject is a human.

73. The method of any one of claims 70 to 72, wherein the subject has been diagnosed with a need for inhibiting NOX4 signaling to the administering step.

74. The method of any one of claims 70 to 72, further comprising identifying a subject in need of inhibition of NOX4 signaling.

75. A method of treating a fibrotic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or wherein is a double bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒;wherein L is ‒(CR11aR11b)2‒ or a structure selected from: ,,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3;wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or(b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1,is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1-C4 alkyl.

76. The method of claim 75, wherein the fibrotic disorder is pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, skeletal muscle fibrosis, or scleroderma or systemic sclerosis.

77. The method of claim 75, wherein the fibrotic disorder is pulmonary fibrosis.

78. The method of claim 77, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.

79. The method of claim 75, wherein the subject is a mammal.

80. The method of claim 75, wherein the mammal is a human.

81. The method of claim 75, wherein the subject has been diagnosed with the fibrotic disorder prior to the administering step.

82. The method of claim 75, further comprising the step of identifying a subject in need of treatment of the fibrotic disorder.

83. The method of claim 75, further comprising administering to the subject an anti-fibrotic agent.

84. The method of claim 83, wherein the anti-fibrotic agent is selected from nintedanib and pirfenidone, 85. A kit comprising a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or whereindouble bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from: ,,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen and C1-C4 alkyl; and wherein R12bis selected from C1-C4 alkyl and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino,C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, provided that when either: (a) A is ‒C(O)‒; or (b) L is ‒(CR11aR11b)2‒, then R3is ‒NR12aR12band R12bcannot be C1-C4 alkyl, and provided that when n is 1,is a single bond, Q1is ‒CH2‒, and Q2is ‒CH2‒ or ‒C(O)‒, then R12ais hydrogen or C1-C4 alkyl, and one or more selected from: a. an anti-fibrotic agent; and b. instructions for treating a fibrotic disorder.

86. The kit of claim 85, wherein the agent is selected from nintedanib and pirfenidone.

87. The kit of claim 85, wherein the compound and the agent are co-formulated.

88. The kit of claim 85, wherein the compound and the agent are co-packaged.

89. A method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or whereindouble bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from:,,,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R3is selected from ‒NR12aR12band Ar1; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl,or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

90. The method of claim 89, wherein administering is via intravenous (IV) or oral administration.

91. The method of claim 89, wherein administering is via inhalation.

92. The method of any one of claims 89 to 91, wherein the subject is a mammal.

93. The method of any one of claims 89 to 91, wherein the mammal is a human.

94. The method of any one of claims 89 to 93, wherein the subject has been diagnosed with ARDS prior to the administering step.

95. The method of any one of claims 89 to 93, wherein the subject has been diagnosed with coronavirus disease (COVID) prior to the administering step.

96. The method of claim 95, wherein COVID is coronavirus disease 2019 (COVID-19).

97. The method of claim 89, wherein the subject has not been diagnosed as having a fibrotic disease prior to the administering step.

98. The method of claim 89, wherein the subject has not been diagnosed as having pulmonary fibrosis prior to the administering step.

99. The method of claim 89, further comprising the step of identifying a subject in need of treatment of ARDS.

100. The method of claim 89, further comprising administering to the subject an agent known to treat ARDS.

101. The method of claim 100, wherein the agent is selected from nitric oxide, a corticosteroid, and an anti-inflammatory agent.

102. The method of claim 101, wherein the corticosteroid is selected from cortisone, hydrocortisone, and prednisone.

103. The method of claim 101, wherein the anti-inflammatory agent is selected from ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, indomethacin, or aspirin.

104. A kit comprising a compound having a structure represented by a formula:, wherein n is 0 or 1; wherein m is 1 or 2; wherein single bond, Q1is ‒CR10aR10b‒, and Q2is ‒CR10cR10d‒ or ‒C(O)‒; wherein each of R10a, R10b, R10c, and R10dis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R10cand R10dtogether comprise =O, or whereindouble bond, Q1is ‒N=, and Q2is ‒CH=; wherein A is selected from ‒C(O)‒ and ‒SO2‒; wherein L is ‒(CR11aR11b)2‒ or a structure selected from: ,,wherein each occurrence of R11aand R11bis independently selected from hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl, or wherein each of R11aand R11btogether comprise =O; wherein each of R1a, R1b, R1c, and R1dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein R2, when present, is selected from hydrogen and C1-C4 alkyl; wherein R12ais selected from hydrogen, C1-C4 alkyl, and Ar2; wherein Ar2is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; and wherein R12bis selected from C1-C4 alkyl, ‒CH2Ar3, and Ar3; wherein Ar3is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒ NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, or wherein each of R12aand R12btogether comprise a C2-C5 heterocycloalkyl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒ OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;wherein Ar1is selected from C6-C14 aryl and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), Cy1, ‒OCy1, and ‒ NH(CH2)oCy1; wherein o is selected from 0, 1, and 2; and wherein Cy1is selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C6- C14 aryl, and C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2- C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, and one or more selected from: a. an agent known to treat ARDS; and b. instructions for treating ARDS.

105. The kit of claim 104, wherein the agent is selected from nitric oxide, a corticosteroid, and an anti-inflammatory agent.

106. The kit of claim 104, wherein the compound and the agent are co-formulated.

107. The kit of claim 104, wherein the compound and the agent are co-packaged.

108. A compound selected from:,or a pharmaceutically acceptable salt thereof.

109. A pharmaceutical composition comprising an effective amount of the compound of claim 108, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

110. A method of inhibiting NADPH Oxidase 4 (NOX4) signaling in a cell, the method comprising contacting the cell with an effective amount of the compound of claim 108, or a pharmaceutically acceptable salt thereof.

111. A method of inhibiting NADPH Oxidase 4 (NOX4) signaling in a subject, the method comprising administering to the subject an effective amount of the compound of claim 108, or a pharmaceutically acceptable salt thereof.

112. A method of treating a fibrotic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 108, or a pharmaceutically acceptable salt thereof.

113. A method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 108, or a pharmaceutically acceptable salt thereof.

114. A kit comprising the compound of claim 108, or a pharmaceutically acceptable salt thereof, and one or more selected from: a) an anti-fibrotic agent; b) instructions for treating a fibrotic disorder; c) an agent known to treat ARDS; and d) instructions for treating ARDS.

115. A compound selected from:,,,, or a pharmaceutically acceptable salt thereof.

116. A pharmaceutical composition comprising an effective amount of the compound of claim 115 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

117. A method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 115 or a pharmaceutically acceptable salt thereof.

118. The method of claim 117, wherein administering is via intravenous (IV) or oral administration.

119. The method of claim 117, wherein administering is via inhalation.

120. The method of claim 117, wherein the subject is a mammal.

121. The method of claim 117, wherein the mammal is a human.

122. The method of claim 117, wherein the subject has been diagnosed with ARDS prior to the administering step.

123. The method of claim 117, wherein the subject has been diagnosed with coronavirus disease (COVID) prior to the administering step.

124. The method of claim 123, wherein COVID is coronavirus disease 2019 (COVID-19).

125. The method of claim 117, wherein the subject has not been diagnosed as having a fibrotic disease prior to the administering step.

126. The method of claim 117, wherein the subject has not been diagnosed as having pulmonary fibrosis prior to the administering step.

127. The method of claim 117, further comprising the step of identifying a subject in need of treatment of ARDS.

128. The method of claim 117, further comprising administering to the subject an agent known to treat ARDS.

129. The method of claim 128, wherein the agent is selected from nitric oxide, a corticosteroid, and an anti-inflammatory agent.

130. The method of claim 129, wherein the corticosteroid is selected from cortisone, hydrocortisone, and prednisone.

131. The method of claim 129, wherein the anti-inflammatory agent is selected from ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, indomethacin, or aspirin.

132. A kit comprising the compound of claim 115, and one or more selected from: a) an agent known to treat ARDS; and b) instructions for treating ARDS.

133. The kit of claim 132, wherein the agent is selected from nitric oxide, a corticosteroid, and an anti-inflammatory agent.

134. The kit of claim 132, wherein the compound and the agent are co-formulated.

135. The kit of claim 132, wherein the compound and the agent are co-packaged.

136. A method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein q is 1 or 2; wherein each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein each of R6aand R6bis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R6aand R6btogether comprise =O; and wherein R7is selected from hydrogen and C1-C4 alkyl; and wherein R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2(C1-C4 alkyl), ‒ SO2NR13aR13b, ‒C(O)Cy2, and ‒SO2Cy2; wherein each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3; and wherein Cy3, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1- C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl; andwherein Cy2, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr1, and ‒NH(CH2)rAr3; wherein r is 0, 1, or 2; and wherein Ar3, when present, is selected from C6 aryl and C2-C5 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4; wherein each of R14aand R14b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy5; and wherein Cy5, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1- C4) dialkylamino, and C1-C4 aminoalkyl; wherein Cy4, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1- C4 aminoalkyl, or a pharmaceutically acceptable salt thereof.

137. The method of claim 136, wherein q is 1.

138. The method of claim 136, wherein at least two of R5a, R5b, R5c, and R5dis hydrogen.

139. The method of claim 136, wherein at least three of R5a, R5b, R5c, and R5dis hydrogen.

140. The method of claim 136, wherein each of R5a, R5b, R5c, and R5dis hydrogen.

141. The method of claim 136, wherein each of R6aand R6bis hydrogen.

142. The method of claim 136, wherein each of R6aand R6btogether comprise =O.

143. The method of claim 136, wherein R7is selected from hydrogen and C1-C4 alkyl, and wherein R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2NR13aR13b, ‒ C(O)Cy2, and ‒SO2Cy2.

144. The method of claim 136, wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4.

145. The method of claim 144, wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl selected from piperidinyl, morpholinyl, and tetrahydropyranyl, and are substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4.

146. The method of claim 136, wherein R7is ‒SO2NR13aR13b.

147. The method of claim 146, wherein one of R13aand R13bis hydrogen and the other is Cy3.

148. The method of claim 146, wherein each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl.

149. The method of claim 146, wherein each of R13aand R13btogether comprise an unsubstituted C4-C5 heterocycloalkyl.

150. The method of claim 136, wherein R8is ‒SO2Cy2.

151. The method of claim 150, wherein Cy2is a C6-C14 aryl substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒ NHC(O)(C1-C4 alkyl), ‒OAr3, and ‒NH(CH2)rAr3.

152. The method of claim 150, wherein Cy2is a C6 aryl monosubstituted with a group selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr3, and ‒NH(CH2)rAr3.

153. The method of claim 136, wherein the compound has a structure:, or a pharmaceutically acceptable salt thereof.

154. The method of claim 136, wherein the compound has a structure:, or a pharmaceutically acceptable salt thereof.

155. The method of claim 136, wherein the compound has a structure:, or a pharmaceutically acceptable salt thereof.

156. The method of claim 136, wherein the compound has a structure:, or a pharmaceutically acceptable salt thereof.

157. The method of claim 136, wherein the compound has a structure:, or a pharmaceutically acceptable salt thereof.

158. The method of claim 136, wherein the compound has a structure:, or a pharmaceutically acceptable salt thereof.

159. The method of claim 136, wherein the compound is selected from:,,or a pharmaceutically acceptable salt thereof.

160. The method of claim 136, wherein the compound is selected from:,,, or a pharmaceutically acceptable salt thereof.

161. A kit comprising a compound having a structure represented by a formula:, wherein q is 1 or 2; wherein each of R5a, R5b, R5c, and R5dis independently selected from hydrogen, halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1- C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; wherein each of R6aand R6bis independently selected from hydrogen and C1-C4 alkyl, or wherein each of R6aand R6btogether comprise =O; and wherein R7is selected from hydrogen and C1-C4 alkyl; and wherein R8is selected from hydrogen, C1-C4 alkyl, ‒C(O)NR13aR13b, ‒SO2NR13aR13b, ‒ C(O)Cy2, and ‒SO2Cy2; wherein each of R13aand R13b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy3; andwherein Cy3, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒ NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1- C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R13aand R13btogether comprise an unsubstituted C2-C5 heterocycloalkyl; and wherein Cy2, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, ‒C(O)NH2, ‒NHC(O)(C1-C4 alkyl), ‒OAr3, and ‒NH(CH2)rAr3; wherein r is 0, 1, or 2; and wherein Ar3, when present, is selected from C6 aryl and C2-C5 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒ CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl; or wherein each of R7and R8together comprise a C2-C5 heterocycloalkyl substituted with 0 or 1 group selected from ‒SO2NR14aR14band ‒SO2Cy4; wherein each of R14aand R14b, when present, is independently selected from hydrogen, C1-C4 alkyl, and Cy5; and wherein Cy5, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1- C4) dialkylamino, and C1-C4 aminoalkyl; wherein Cy4, when present, is selected from a C3-C6 cycloalkyl, a C3-C6 heterocycloalkyl, a C6-C14 aryl, and a C2-C10 heteroaryl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, ‒CN, ‒NH2, ‒OH, ‒NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1- C4 aminoalkyl, or a pharmaceutically acceptable salt thereof, and one or more selected from: a) an agent known to treat ARDS; and b) instructions for treating ARDS.

Images